UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

FADI DAHHAN, Individual	ly and on Behalf) No. 1:17-cv-10511-IT
of All Others Similarly Situa	ted,)
•	,) <u>CLASS ACTION</u>
	Plaintiff,	,)
	•	DECLARATION OF ROSS D. MURRAY
vs.		REGARDING NOTICE
) DISSEMINATION, PUBLICATION,
OVASCIENCE, INC., et al.,) AND REQUESTS FOR EXCLUSION
	Defendants.) RECEIVED TO DATE
		<i>)</i>

I, ROSS D. MURRAY, declare and state as follows:

- 1. I am employed as a Vice President of Securities by Gilardi & Co. LLC ("Gilardi"), located at 1 McInnis Parkway, Suite 250, San Rafael, California. The following statements are based on my personal knowledge and information provided to me by other Gilardi employees and if called to testify I could and would do so competently.
- 2. Pursuant to this Court's April 1, 2022 Order Preliminarily Approving Settlement and Providing for Notice ("Notice Order") (ECF 178), Gilardi was appointed to supervise and administer the notice procedure as well as the processing of claims in connection with the proposed Settlement of the above-captioned action (the "Action"). I oversaw the notice services that Gilardi provided in accordance with the Notice Order.
- 3. I submit this declaration in order to provide the Court and the parties to the Action with information regarding: (i) mailing of the Court-approved Notice of (I) Proposed Settlement and Plan of Allocation; (II) Settlement Hearing; and (III) Motion for Attorneys' Fees and Litigation Expenses (the "Notice") and Proof of Claim and Release Form (the "Proof of Claim") (collectively, the "Claim Package," attached hereto as Exhibit A); (ii) publication of the Summary Notice of (I) Proposed Settlement and Plan of Allocation; (II) Settlement Hearing; and (III) Motion for Attorneys' Fees and Litigation Expenses (the "Summary Notice"); (iii) updating of the website and toll-free telephone number dedicated to this Settlement; and (iv) the number of requests for exclusion from the Class received to date by Gilardi.

DISSEMINATION OF THE CLAIM PACKAGE

4. Pursuant to the Notice Order, Gilardi is responsible for disseminating the Claim Package to potential Class Members. The Class consists of all persons or entities who purchased or otherwise acquired the publicly-traded common stock of OvaScience, Inc. ("OvaScience" or the "Company") between December 17, 2014 and September 28, 2015, inclusive (the "Class

¹ All capitalized terms that are not otherwise defined herein shall have the same meanings provided in the Stipulation and Agreement of Settlement dated March 4, 2022 (the "Stipulation") (ECF 174).

- Period"). Excluded from the Class are: (i) Defendants; (ii) the officers and directors of OvaScience, at all relevant times; (iii) members of their immediate families, and their legal representatives, heirs, successors, or assigns; and (iv) any entity in which Defendants have or had a controlling interest. Also excluded from the Class are (i) the persons and entities who timely and validly requested exclusion from the Class in connection with the Class Notice; and (ii) any persons or entities who exclude themselves by submitting a request for exclusion in connection with the Notice.
- 5. Gilardi used the previous list of stockholders compiled in connection with dissemination of the Notice of Pendency of Class Action (the "Notice of Pendency") in 2020 as the basis for the mailing list for the Claim Package, as the Class definition and Class Period have not changed since the mailing list was compiled for the Notice of Pendency. The list was reviewed to identify and eliminate duplicate entries and incomplete data, resulting in a usable mailing list of 12,508 unique names and addresses. Gilardi had the unique name and address data printed on to Claim Packages, posted the Claim Packages for First-Class Mail, postage prepaid, and delivered 12,508 Claim Packages on April 22, 2022, to the United States Post Office for mailing.
- 6. In addition, on April 22, 2022, as part of its normal mailing procedures, Gilardi mailed, by First-Class Mail, Claim Packages and cover letters to 281 brokerages, custodial banks, and other institutions ("Nominee Holders") that hold securities in "street name" as nominees for the benefit of their customers who are the beneficial owners of the securities. The Nominee Holders also include a group of filers/institutions who have requested notification of every securities case. These Nominee Holders are included in a proprietary database created and maintained by Gilardi. In Gilardi's experience, the Nominee Holders included in this proprietary database represent a significant majority of the beneficial holders of securities. The cover letter accompanying the Claim Packages advised the Nominee Holders of the proposed Settlement and requested their cooperation in forwarding the Claim Packages to potential Class Members. In the more than three decades that Gilardi has been providing notice and claims administration services in securities class actions, Gilardi has found the majority of potential class members hold their

securities in street name and are notified through the Nominee Holders. Gilardi also mailed Claim Packages and cover letters to the 4,445 institutions included on the U.S. Securities and Exchange Commission's ("SEC") list of active brokers and dealers at the time of mailing. A sample of the cover letter mailed to Nominee Holders and the institutions included on the SEC's list of active brokers and dealers is attached hereto as Exhibit B.

- 7. On April 22, 2022, Gilardi also delivered electronic copies of the Claim Package to 365 registered electronic filers who are qualified to submit electronic claims. These filers are primarily institutions and third-party filers who typically file numerous claims on behalf of beneficial owners for whom they act as trustees or fiduciaries.
- 8. As part of the notice program for this Action, on April 22, 2022, Gilardi also delivered electronic copies of the Claim Package via email to be published by the Depository Trust Company ("DTC") on the DTC Legal Notice System ("LENS"). LENS enables the participating bank and broker nominees to review the Claim Package and contact Gilardi for copies of the Claim Package for their beneficial holders.
- 9. Gilardi has acted as a repository for shareholder and nominee inquiries and communications received in this Action. In this regard, Gilardi has forwarded the Claim Package on request to nominees who held, purchased or acquired OvaScience common stock for the beneficial interest of other persons. Gilardi has also forwarded the Claim Package directly to beneficial owners upon receipt of the names and addresses from such beneficial owners or nominees.
- 10. Following the initial mailing, Gilardi received 14 responses to the outreach efforts described above which included computer files containing a total of 2,975 names and addresses of potential Class Members. In addition, 21 institutions requested that Gilardi send them a total of 11,820 Claim Packages for forwarding directly to their clients. Gilardi has also received four responses that included mailing labels with the name and address of five potential Class Members. Gilardi has also mailed 69 Claim Packages as a result of returned mail for which new addresses

were identified for re-mailing to those potential Class Members. Each of these requests has been completed in a timely manner.

11. As of June 21, 2022, Gilardi has mailed a total of 32,468 Claim Packages to potential Class Members and nominees.

PUBLICATION OF THE SUMMARY NOTICE

12. In accordance with the Notice Order, on May 6, 2022, Gilardi caused the Summary Notice to be published in *The Wall Street Journal* and transmitted over *PR Newswire*, as shown in the confirmations of publication attached hereto as Exhibit C.

TELEPHONE HELPLINE AND WEBSITE

- 13. On July 6, 2020, in connection with the mailing of the Notice of Pendency, Gilardi established and continues to maintain a case-specific, toll-free telephone helpline, 1-866-757-7818, to accommodate potential Class Member inquiries. The toll-free number was set forth in the Notice, the Summary Notice, and on the case website. Gilardi has been and will continue to promptly respond to all inquiries to the toll-free telephone helpline.
- 14. On July 6, 2020, in connection with the mailing of the Notice of Pendency, Gilardi established and continues to maintain a website dedicated to this Action (www.OvaScienceSecuritiesLitigation.com) to provide additional information to Class Members and to provide answers to frequently asked questions. The web address was set forth in the Claim Package and the Summary Notice. The website includes information regarding the Action and the Settlement, including the objection and claim filing deadlines, and the date, time, and location of the Court's Settlement Hearing. Copies of the Notice, Proof of Claim, Stipulation, Notice Order, Notice of Pendency, and Order Granting Class Representative's Uncontested Motion for Entry of an Order Approving Notice of Pendency of Class Action, Notice Procedures, and Appointment of Notice Administrator are posted on the website and are available for downloading. Class Members can also complete and submit a Proof of Claim through the website. In addition, Class Members may email Gilardi at info@OvaScienceSecuritiesLitigation.com with any inquiries.

REQUESTS FOR EXCLUSION RECEIVED TO DATE

- 15. The Notice of Pendency informed potential Class Members that written requests for exclusion from the Class were to be mailed to *OvaScience Securities Litigation*, c/o Gilardi & Co. LLC, 150 Royall Street, Suite 101, Canton, MA 02021, such that they were postmarked no later than September 4, 2020.
- 16. The Notice of Pendency also set forth the information that was to be included in each request for exclusion. In response to the Notice of Pendency, Gilardi received four timely requests for exclusion. Redacted copies of those requests for exclusion were submitted to the Court in my October 2, 2020 Declaration. (ECF 123).
- 17. The Notice provided in connection with this Settlement informed potential Class Members that written requests for exclusion from the Class are to be mailed to *OvaScience Securities Litigation*, Claims Administrator, c/o Gilardi & Co. LLC, EXCLUSIONS, 150 Royall Street, Suite 101, Canton, MA 02021, such that they are postmarked no later than July 5, 2022.
- 18. The Notice also sets forth the information that is to be included in each request for exclusion. As of the date of this declaration, Gilardi has received two timely requests for exclusion in connection with this Settlement, reducted copies of which are attached hereto as Exhibit D.

I declare under penalty of perjury that the foregoing is true and correct and that this declaration was executed this 21st day of June, 2022, at San Rafael, California.

ROSS D. MURRAY

CERTIFICATE OF SERVICE

I hereby certify that this document, filed through the ECF system will, be sent electronically to the registered participants as identified on the Notice of Electronic Filing (NEF) and paper copies will be sent to those indicated as non-registered participants, if any, on June 21, 2022.

s/ Stephen R. Astley
STEPHEN R. ASTLEY

EXHIBIT A

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

FADI DAHHAN, Individually ar Others Similarly Situated,	nd on Behalf of All Plaintiff,)))	No. 1:17-cv-10511-IT CLASS ACTION
VS.		ĺ	
OVASCIENCE, INC., et al.,)	
	Defendants.)	

NOTICE OF (I) PROPOSED SETTLEMENT AND PLAN OF ALLOCATION; (II) SETTLEMENT HEARING; AND (III) MOTION FOR ATTORNEYS' FEES AND LITIGATION EXPENSES

TO: All persons or entities who purchased or acquired OvaScience, Inc. ("OvaScience" or the "Company") common stock between December 17, 2014 and September 28, 2015, inclusive (the "Class")

A Federal Court authorized this Notice. This is not a solicitation from a lawyer.

Notice of Settlement: This Notice has been sent to you pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Massachusetts (the "Court"). Please be advised that lead plaintiff and Class Representative Freedman Family Investments LLC, on behalf of itself and the Court-certified Class (as defined in ¶34 below), has reached a proposed settlement of the above-captioned securities class action ("Action") for a total of \$15,000,000 in cash that, if approved, will resolve all claims in the Action (the "Settlement"). The terms and provisions of the Settlement are contained in the Stipulation and Agreement of Settlement dated March 4, 2022 (the "Stipulation").

This Notice is directed to you in the belief that you may be a member of the Class. If you do not meet the Class definition, or if you previously excluded yourself from the Class in connection with the Notice of Pendency of Class Action that was mailed to potential Class Members beginning in July 2020 (the "Class Notice"), this Notice does not apply to you. A list of the persons and entities who requested exclusion from the Class pursuant to the Class Notice is available at www.OvaScienceSecuritiesLitigation.com.

PLEASE READ THIS NOTICE CAREFULLY. This Notice explains important rights you may have, including the possible receipt of a payment from the Settlement. If you are a member of the Class, your legal rights will be affected whether or not you act.

If you have any questions about this Notice, the proposed Settlement, or your eligibility to participate in the Settlement, please DO NOT contact the Court, the Clerk's office, OvaScience, the other Defendants in the Action, or their counsel. All questions should be directed to Lead Counsel or the Claims Administrator (see ¶6 below).

- 1. <u>Description of the Action and the Class</u>: This Notice relates to a proposed settlement of claims in a pending securities class action brought by investors alleging, among other things, that defendants OvaScience, Inc. ("OvaScience" or the "Company"), Longwood Fund, L.P., Longwood Fund, GP, LLC ("Longwood Funds"), and Michelle Dipp, Jeffrey E. Young, and Richard Aldrich ("Individual Defendants") (collectively, "Defendants" and, together with Lead Plaintiff, "Parties"), violated the federal securities laws by making false and misleading statements concerning OvaScience's AUGMENT treatment for infertility. A more detailed description of the Action is set forth in ¶¶11-33 below. The proposed Settlement, if approved by the Court, will settle claims of the Class, as defined in ¶34 below.
- 2. <u>Statement of the Class's Recovery</u>: Subject to Court approval, Lead Plaintiff, on behalf of itself and the Class, has agreed to settle the Action in exchange for \$15,000,000 in cash (the "Settlement Amount") to be deposited into an escrow account. The Net Settlement Fund (*i.e.*, the Settlement Amount plus any and all interest earned thereon (the "Settlement Fund") less (i) any Taxes; (ii) any Notice and Administration Costs; (iii) any Litigation Expenses awarded by the Court; (iv) any attorneys' fees awarded by the Court; and (v) any other costs or fees approved by the Court) will be distributed in accordance with a plan of allocation that is approved by the Court. The proposed plan of allocation (the "Plan of Allocation") is set forth in Appendix A at the end of this Notice. The Plan of Allocation will determine how the Net Settlement Fund shall be allocated among members of the Class.

All capitalized terms used in this Notice that are not otherwise defined herein shall have the meanings ascribed to them in the Stipulation. The Stipulation is available at www.OvaScienceSecuritiesLitigation.com.

- 3. <u>Estimate of Average Amount of Recovery Per Share</u>: Based on Lead Plaintiff's estimate of the number of shares of OvaScience common stock purchased or acquired during the Class Period that may have been affected by the conduct at issue in the Action, the estimated average recovery (before the deduction of any Court-approved fees, expenses, and costs as described herein) is \$0.44 per affected OvaScience share. Class Members should note, however, that the foregoing average recovery is only an estimate. Some Class Members may recover more or less than the estimated amount depending on, among other factors, when and at what prices they purchased or acquired or sold their OvaScience common stock, and the total number and value of valid Claim Forms submitted. Distributions to Class Members will be made based on the Plan of Allocation set forth in Appendix A or such other plan of allocation as may be ordered by the Court.
- 4. **Average Amount of Damages Per Share:** The Parties do not agree on the average amount of damages per OvaScience share that would be recoverable if Lead Plaintiff were to prevail in the Action. Among other things, Defendants vigorously deny the assertion that they violated the federal securities laws or that any damages were suffered by any members of the Class as a result of Defendants' alleged conduct.
- 5. Attorneys' Fees and Expenses Sought: Plaintiff's Counsel, which have been prosecuting the Action on a wholly contingent basis, have not received any payment of attorneys' fees for their representation of the Class and have advanced the funds to pay expenses necessarily incurred to prosecute the Action. Court-appointed Lead Counsel, Jack Reise, Stephen R. Astley, and Elizabeth Shonson of Robbins Geller Rudman & Dowd LLP ("Lead Counsel" or "RGRD"), will apply to the Court for an immediate award of attorneys' fees on behalf of all Plaintiff's Counsel in an amount not to exceed 33-1/3% of the Settlement Fund, plus interest. In addition, Lead Counsel will apply for payment of Plaintiff's Counsel's Litigation Expenses in connection with the institution, prosecution, and resolution of the Action in an amount not to exceed \$875,000, plus interest, which amount may include an application for reimbursement of the reasonable costs and expenses incurred by Lead Plaintiff directly related to its representation of the Class, pursuant to the Private Securities Litigation Reform Act of 1995 ("PSLRA"). Any fees and expenses awarded by the Court will be paid from the Settlement Fund. Class Members are not personally liable for any such fees or expenses. The estimated average cost for such fees and expenses, if the Court approves Lead Counsel's fee and expense application, is \$0.17 per affected OvaScience common stock.
- 6. <u>Identification of Attorneys' Representative</u>: Lead Plaintiff and the Class are represented by Ellen Gusikoff Stewart, Esq. of Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, 1-800-449-4900, settlementinfo@rgrdlaw.com. Further information regarding the Action, the Settlement, and this Notice may be obtained by contacting Lead Counsel or the Claims Administrator at: *OvaScience Securities Litigation*, c/o Gilardi & Co. LLC, P.O. Box 43312, Providence, RI 02940-3312, 1-866-757-7818, info@OvaScienceSecuritiesLitigation.com, www.OvaScienceSecuritiesLitigation.com. **Please do not contact the Court regarding this Notice.**
- 7. Reasons for the Settlement: Lead Plaintiff's principal reason for entering into the Settlement is the substantial and certain recovery that the Settlement provides for the Class without the risk or the delays inherent in further litigation. The substantial recovery provided under the Settlement must be considered against the significant risk that a smaller recovery or indeed no recovery at all might be achieved after a contested summary judgment motion, a trial of the Action, and the likely appeals that would follow a trial. This process would be expected to last several years. Defendants, who deny all allegations of wrongdoing, are entering into the Settlement solely to eliminate the uncertainty, burden, and expense of further protracted litigation.

YOUR LEG	GAL RIGHTS AND OPTIONS IN THE SETTLEMENT
SUBMIT A CLAIM FORM	This is the only way to be eligible to receive a payment from the Settlement
POSTMARKED (IF MAILED), OR	Fund. If you are a Class Member, you will be bound by the Settlement as
ONLINE, NO LATER THAN	approved by the Court and you will give up any Released Plaintiff's Claims
AUGUST 22, 2022	(defined in ¶43 below) that you have against Defendants and the other
	Defendants' Releasees (defined in ¶44 below), so it is in your interest to submit
	a Claim Form.
EXCLUDE YOURSELF	If you exclude yourself from the Class, you will not be eligible to receive any
	payment from the Settlement Fund. This is the only option that allows you to
	ever be part of any other lawsuit against the Defendants or any Defendants'
	Releasees concerning the Released Plaintiff's Claims.
	Exclusions must be postmarked on or before July 5, 2022. If you excluded yourself from the Class in connection with the Notice of Pendency of Class
	Action provided in or around July 2020, you do not have to do so again.
OBJECT TO THE SETTLEMENT	If you do not like the proposed Settlement, the proposed Plan of Allocation, or
BY SUBMITTING A WRITTEN	the request for attorneys' fees and Litigation Expenses, you may write to the
OBJECTION SO THAT IT IS	Court and explain why you do not like them. You cannot object to the
RECEIVED NO LATER THAN	Settlement, the Plan of Allocation, or the fee and expense request unless you
JULY 5, 2022	are a Class Member.
GO TO A HEARING ON	Filing a written objection and notice of intention to appear by July 5, 2022
JULY 26, 2022 AT 2:45 P.M., AND	allows you to speak in Court, at the discretion of the Court, about the fairness
FILE A NOTICE OF INTENTION	of the proposed Settlement, the Plan of Allocation, and/or the request for
TO APPEAR SO THAT IT IS	attorneys' fees and Litigation Expenses. In the Court's discretion, the
RECEIVED NO LATER THAN	July 26, 2022 hearing may be conducted by telephone or video conference
JULY 5, 2022	(see ¶65 below). If you submit a written objection, you may (but you do not
	have to) participate in the hearing and, at the discretion of the Court, speak to
	the Court about your objection.
DO NOTHING	If you are a member of the Class and you do not submit a valid Claim Form,
	you will not be eligible to receive any payment from the Settlement Fund. You
	will, however, remain a member of the Class, which means that you will be
	bound by any judgments or orders entered by the Court in the Action.

These rights and options – and the deadlines to exercise them – are further explained in this Notice. <u>Please Note</u>: The date and time of the Settlement Hearing – currently scheduled for July 26, 2022 at 2:45 p.m. – is subject to change without further notice to the Class. It is also within the Court's discretion to hold the hearing in person or by video or telephonic conference. If you plan to attend the hearing, you should check the case website, www.OvaScienceSecuritiesLitigation.com, or with Lead Counsel as set forth above to confirm that no change to the date and/or time of the hearing has been made.

WHY DID I GET THIS NOTICE?

- 8. The Court directed that this Notice be mailed to you because you or someone in your family or an investment account for which you serve as a custodian may have purchased or acquired OvaScience common stock during the period between December 17, 2014 and September 28, 2015, inclusive (the "Class Period"). The Court has directed us to send you this Notice because, as a potential Class Member, you have a right to know about your options before the Court rules on the proposed Settlement. If the Court approves the Settlement and the Plan of Allocation (or some other plan of allocation), the Claims Administrator selected by Lead Plaintiff and approved by the Court will make payments pursuant to the Settlement after any objections and appeals are resolved.
- 9. The purpose of this Notice is to inform you of the terms of the proposed Settlement of the Action and of a hearing to be held by the Court to consider the fairness, reasonableness, and adequacy of the Settlement, the proposed Plan of Allocation, and the motion by Lead Counsel for an award of attorneys' fees and payment of Litigation Expenses (the "Settlement Hearing"). See ¶¶63-65 below for details about the Settlement Hearing, including the date and location of the hearing.
- 10. The issuance of this Notice is not an expression of any opinion by the Court concerning the merits of any claim in the Action, and the Court still must decide whether to approve the Settlement. If the Court approves the Settlement and a plan of allocation, then payments to Authorized Claimants will be made after any appeals are resolved and after the completion of all claims processing. Please be patient, as this process can take some time to complete.

WHAT IS THIS CASE ABOUT?

- 11. OvaScience was a pharmaceutical company that sought to develop commercially-available fertility treatments. During the Class Period, OvaScience's common stock traded on the NASDAQ market under ticker symbol OVAS.
- 12. Beginning on or about March 24, 2017, several related securities class actions brought on behalf of investors in OvaScience common stock were filed in the Court. On July 5, 2017, the Court entered a Memorandum & Order appointing Freedman Family Investments LLC as "Lead Plaintiff" for the Action and appointing RGRD as "Lead Counsel."
- 13. On August 25, 2017, Lead Plaintiff filed an amended complaint in the Action, the Amended Class Action Complaint (the "Complaint"). The Complaint asserts claims against OvaScience and Dipp under Section 10(b) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, and against Dipp and Young under Section 20(a) of the Exchange Act (OvaScience, Dipp, and Young are, collectively, the "OvaScience Defendants"). Among other things, the Complaint alleges that, during the Class Period, the OvaScience Defendants knowingly or recklessly misrepresented and concealed material facts regarding the efficacy and commercial viability of AUGMENT. More specifically, the Complaint alleges that throughout the Class Period, the OvaScience Defendants made numerous public statements that led investors to believe that AUGMENT worked, and that there was significant demand from patients, which caused OvaScience's common stock to allegedly trade at artificially inflated prices during the Class Period. The Complaint further alleges that the price of OvaScience stock declined when the true facts concerning the OvaScience Defendants' alleged misrepresentations and omissions were revealed, resulting in financial losses to those who purchased or acquired OvaScience common stock during the Class Period at the inflated prices.
- 14. On October 10, 2017, the OvaScience Defendants filed a motion to dismiss the Complaint, which was fully briefed and argued by December 11, 2017. On July 31, 2018, the Court issued a Memorandum & Order denying the OvaScience Defendants' motion to dismiss in its entirety.
 - 15. On August 14, 2018, the OvaScience Defendants filed their answer to the Complaint.
- 16. On March 14, 2019, Lead Plaintiff filed a motion for class certification ("Class Certification Motion"). The OvaScience Defendants filed their opposition to the Class Certification Motion on April 29, 2019, and Lead Plaintiff filed its reply brief on June 13, 2019.
- 17. With the benefit of the evidence produced to Lead Plaintiff by the OvaScience Defendants, the Class filed a motion for leave to file a Second Amended Class Action Complaint ("Second Amended Complaint") on December 10, 2019, adding the Longwood Funds and Aldrich as new defendants for their alleged active role in the fraud through their exercise of control and influence over primary violators OvaScience and Dipp.²
- 18. On December 30, 2019, the Court granted the Parties' request to stay litigation proceedings pending an upcoming mediation. Lead Plaintiff and the OvaScience Defendants exchanged mediation statements and participated in a mediation before Michelle Yoshida on March 3, 2020, but the mediation did not result in resolution of the litigation. The stay was thereafter lifted on April 2, 2020.
- 19. Pursuant to an agreed-upon, Court-approved schedule, the OvaScience Defendants moved to strike the Second Amended Complaint and the Longwood Defendants moved to dismiss the Second Amended Complaint on May 1, 2020.
- 20. On May 8, 2020, the Court granted the Class Certification Motion, appointing Freedman Family Investments LLC as "Class Representative," and on May 18, 2020, appointed Jack Reise, Stephen R. Astley, and Elizabeth Shonson of RGRD as Class Counsel.
- 21. On June 15, 2020, the Court entered an Order granting Lead Plaintiff's unopposed motion to approve the form and manner of providing notice to potential Class Members (the "Class Notice") to notify them of, among other things: (i) the Action pending against Defendants; (ii) the Court's certification of the Action to proceed as a class action on behalf of the Class; (iii) their right to request to be excluded from the Class; (iv) the effect of remaining in the Class or requesting exclusion; and (v) the requirements for requesting exclusion. The deadline for requesting exclusion from the Class pursuant to the Class Notice was September 4, 2020.

The Court granted Lead Plaintiff's oral emergency motion for leave to file the Second Amended Complaint, subject to a motion to strike by the OvaScience Defendants. The Second Amended Complaint was thereafter filed under seal. The seal was lifted June 7, 2021, and the Second Amended Complaint was filed on the public docket on June 29, 2021.

- 22. While the motions to strike and to dismiss the Second Amended Complaint were pending, Lead Plaintiff and the OvaScience Defendants continued to litigate the case until, once again, on August 14, 2020, they jointly sought a stay of the case to engage in a second private mediation as an attempt to resolve the litigation. Lead Plaintiff and the OvaScience Defendants exchanged supplemental mediation statements, and mediated before Judge Daniel Weinstein on November 10, 2020, but were unable to reach a resolution of the case on that day.
- 23. Nevertheless, counsel for the parties and insurance carriers continued discussions with the mediator over the course of several months, but were ultimately unable to reach a mutually agreeable resolution of the litigation.
- 24. On November 19, 2020, while the case remained stayed, the Parties jointly requested that the Court rule upon the still pending Motion to Dismiss the Second Amended Complaint and Motion to Strike the Second Amended Complaint, to aid the Parties in discussions of potential resolution of the case.
- 25. On May 28, 2021, the Court entered her decisions denying Defendants' motions to dismiss and strike the Second Amended Complaint.
- 26. Thereafter, on June 4, 2021, the Parties jointly requested that the stay be lifted, which was entered on June 7, 2021. The Court directed Defendants to answer the Second Amended Complaint, which they did on July 13, 2021.
- 27. On that same day, Lead Plaintiff filed a Second Motion to Compel certain documents that the OvaScience Defendants had withheld on the basis of the attorney-client privilege. The OvaScience Defendants opposed that motion on July 27, 2021 and, Lead Plaintiff filed its reply with Court approval on August 13, 2021.
- 28. Throughout the course of the litigation, the Parties produced approximately 270,000 documents totaling over 1.5 million pages, conducted depositions of four fact witnesses, one expert witness, served and responded to various sets of requests for production, interrogatories, and requests for admission. Lead Plaintiff additionally served subpoenas on 22 third parties, including the SEC, which, collectively, produced approximately 155,000 documents totaling over 1 million pages.
- 29. On December 10, 2021, the Court entered two separate Orders on Lead Plaintiff's First and Second Motions to Compel, granting Lead Plaintiff's request to reopen the depositions of David Harding; ordering the OvaScience Defendants "to produce the bates stamped version of its SEC production, all non-privileged correspondence with the SEC concerning AUGMENT . . . and all documents concerning . . . [the SEC] investigation itself"; and ordering Defendants "to supplement their initial disclosures, no later than fourteen days from the date of this Order, to provide a complete list of individuals (and the subject of discoverable information they may have) that Defendants may use to support this defense, and to provide all documents that Defendants may use to support this defense."
- 30. Pursuant to those Orders, the OvaScience Defendants served Lead Plaintiff with supplemental initial disclosures, and produced a hard drive containing over 377,000 additional pages of discovery previously produced to the SEC as part of its investigation into OvaScience.
- 31. The Parties thereafter continued negotiations with the assistance of Judge Weinstein; and, in response to a mediator's recommendation from him, reached an agreement in principle to settle the Action on January 14, 2022. The Parties agreed to settle and release all claims against Defendants in return for a cash payment by or on behalf of Defendants of \$15,000,000 in cash for the benefit of the Class, subject to certain terms and conditions and the execution of a customary "long form" stipulation and agreement of settlement and related papers.
- 32. After additional negotiations regarding the specific terms of their agreement, the Parties entered into the Stipulation on March 4, 2022. The Stipulation, which sets forth the terms and conditions of the Settlement, can be viewed at www.OvaScienceSecuritiesLitigation.com.
- 33. On March 4, 2022, Lead Plaintiff moved for preliminary approval of the Settlement, and on April 1, 2022, the Court preliminarily approved the Settlement, authorized this Notice to be disseminated to Class Members, and scheduled the July 26, 2022 Settlement Hearing to consider whether to grant final approval to the Settlement.

HOW DO I KNOW IF I AM AFFECTED BY THE SETTLEMENT? WHO IS INCLUDED IN THE CLASS?

34. If you are a member of the Class, you are subject to the Settlement. The Class consists of:

all persons or entities who purchased or otherwise acquired the publicly-traded common stock of OvaScience between December 17, 2014 and September 28, 2015, inclusive.

Excluded from the Class by definition are: Defendants; the officers and directors of OvaScience, at all relevant times; members of their immediate families, and their legal representatives, heirs, successors, or assigns; and any entity in which Defendants have or had a controlling interest. Also excluded from the Class are the persons and entities who

timely and validly requested exclusion from the Class in connection with the Class Notice, and any persons or entities who exclude themselves by submitting a request for exclusion in connection with this Notice, in accordance with the requirements set forth in ¶61 below.

PLEASE NOTE: Receipt of this Notice does not mean that you are a Class Member or that you will be entitled to a payment from the Settlement.

If you are a Class Member and you wish to be eligible to receive a payment from the Settlement, you are required to submit the Claim Form that is being distributed with this Notice, and the required supporting documentation as set forth in the Claim Form, *postmarked* (if mailed), or online through the case website, www.OvaScienceSecuritiesLitigation.com, no later than August 22, 2022.

WHAT ARE LEAD PLAINTIFF'S REASONS FOR THE SETTLEMENT?

- 35. Lead Plaintiff and Lead Counsel believe that the claims asserted against Defendants have merit. They recognize, however, the expense and length of continued proceedings necessary to pursue their claims against Defendants through summary judgment, pre-trial motions, a trial, and appeals, as well as the very substantial risks they would face in establishing liability and damages. For example, with respect to establishing Defendants' liability for violations of the securities laws, Lead Plaintiff faced risks that the Court or the jury would credit Defendants' arguments, including that (i) they made no actionable misstatements or omissions, and (ii) none of the Defendants or any of their agents acted with the requisite intent to commit a violation of the securities laws.
- 36. Lead Plaintiff also faced further risks relating to proof of loss causation and damages. For example, Defendants would have argued at trial that Lead Plaintiff could not establish a causal connection between the alleged misrepresentations and the losses investors allegedly suffered, as required by law. If Defendants had succeeded on one or more of their loss causation and damages arguments, even if Lead Plaintiff had established liability for its securities fraud claims, the recoverable damages could have been substantially less than the amount provided in the Settlement or even zero.
- 37. In light of these risks, the amount of the Settlement, and the immediacy of recovery to the Class, Lead Plaintiff and Lead Counsel believe that the proposed Settlement is fair, reasonable, adequate, and in the best interests of the Class. Lead Plaintiff and Lead Counsel believe that the Settlement provides a substantial benefit to the Class, namely \$15,000,000 in cash (less the various deductions described in this Notice), as compared to the risk that the claims in the Action would produce a smaller recovery, or no recovery, and not until after summary judgment, trial, and appeals, possibly years in the future.
- 38. Defendants have vigorously denied and continue to deny each and all of the claims asserted against them in the Action and deny that the Class was harmed or suffered any damages as a result of the conduct alleged in the Action. Defendants expressly have denied and continue to deny all charges of wrongdoing or liability against them arising out of any of the conduct, statements, acts, or omissions alleged, or that could have been alleged, in the Action. Defendants expressly deny that Lead Plaintiff has asserted any valid claims as to any of them, and expressly deny any and all allegations of fault, liability, wrongdoing, or damages whatsoever. Defendants have agreed to the Settlement solely to eliminate the burden and expense of continued litigation. Accordingly, the Settlement may not be construed as an admission of any wrongdoing by Defendants.

WHAT MIGHT HAPPEN IF THERE WERE NO SETTLEMENT?

39. If there were no Settlement and Lead Plaintiff failed to establish any essential legal or factual element of its claims against Defendants, neither Lead Plaintiff nor the other members of the Class would recover anything from Defendants. Also, if Defendants were successful in proving any of their defenses, either at summary judgment, at trial, or on appeal, the Class could recover substantially less than the amount provided in the Settlement, or nothing at all.

HOW ARE CLASS MEMBERS AFFECTED BY THE SETTLEMENT?

- 40. As a Class Member, you are represented by Lead Plaintiff and Lead Counsel, unless you enter an appearance through counsel of your own choice at your own expense. You are not required to retain your own counsel, but, if you choose to do so, such counsel must file a notice of appearance on your behalf as provided in the section entitled, "When And Where Will The Court Decide Whether To Approve The Settlement?" below.
- 41. If you are a Class Member and you wish to object to the Settlement, the Plan of Allocation, or Lead Counsel's application for attorneys' fees and Litigation Expenses, you may present your objections by following the instructions in the section entitled, "When And Where Will The Court Decide Whether To Approve The Settlement?" below.
- 42. If you are a Class Member, and do not exclude yourself from the Class, you will be bound by any orders issued by the Court. If the Settlement is approved, the Court will enter a judgment (the "Judgment"). The Judgment will dismiss with prejudice the claims in the Action against Defendants and will provide that, upon the Effective Date of the Settlement, Lead Plaintiff and each of the other Class Members, on behalf of themselves, and their respective heirs,

executors, administrators, predecessors, successors, and assigns in their capacities as such, will have fully, finally, and forever compromised, settled, released, resolved, relinquished, waived, and discharged any and all Released Plaintiff's Claims (as defined in ¶43 below) against Defendants and the other Defendants' Releasees (as defined in ¶44 below), and will forever be barred and enjoined from prosecuting any and all Released Plaintiff's Claims against any of the Defendants' Releasees, whether or not such Class Member executes and delivers the Claim Form or shares in the Net Settlement Fund. This Release will not apply to any of the Excluded Plaintiff's Claims (as defined in ¶43 below).

- "Released Plaintiff's Claims" means any and all manner of claims, demands, remedies, rights, liabilities, losses, obligations, duties, damages, costs, debts, expenses, interest, penalties, sanctions, fees, attorneys' fees, actions, potential actions, causes of action, suits, judgments, defenses, counterclaims, offsets, decrees, matters, issues and controversies of any kind, nature or description whatsoever, whether disclosed or undisclosed, accrued or unaccrued, apparent or not apparent, foreseen or unforeseen, matured or not matured, suspected or unsuspected, liquidated or not liquidated, fixed or contingent, including both known and Unknown Claims, (i) that Lead Plaintiff asserted in the Second Amended Complaint: or (ii) that Lead Plaintiff could have asserted against Defendants in any court, tribunal, forum or proceeding, that are based upon, arise out of, or relate to both (a) the actions, inactions, deliberations, discussions, decisions, votes, or any other conduct of any kind by any of the Defendants relating to any agreement, transaction, occurrence, conduct, or fact alleged or set forth in the Second Amended Complaint, and (b) the purchase or acquisition of OvaScience common stock during the Class Period. Released Plaintiff's Claims do not include any of the following claims: (i) any claims asserted in any ERISA, derivative, or consumer action; (ii) any claims by any governmental entity that arise out of any governmental investigation of Defendants relating to the wrongful conduct alleged in the Action; (iii) any claims relating to the enforcement of the Settlement; (iv) claims of the persons and entities who submitted a request for exclusion from the Class in connection with the Class Notice; or (v) claims of any persons or entities who submit a request for exclusion from the Class in connection with this Notice ("Excluded Plaintiff's Claims"), or claims to enforce the Stipulation, the Settlement, or the Judgment.
- 44. "Defendants' Releasees" means Defendants and their respective current and former parents, affiliates, subsidiaries, officers, directors, agents, successors, predecessors, assigns, assignees, partnerships, partners, trustees, trusts, employees, immediate family members, insurers, reinsurers, and attorneys, in their capacities as such.
- 45. "Unknown Claims" means any Released Plaintiff's Claims that Lead Plaintiff or any other Class Members does not know or suspect to exist in his, her, their, or its favor at the time of the release of such claims, and any Released Defendants' Claims that any Defendant does not know or suspect to exist in his, her, or its favor at the time of the release of such claims, which, if known by him, her, them, or it, might have affected his, her, or its decision(s) with respect to this Settlement. With respect to any and all Released Claims, the Parties stipulate and agree that, upon the Effective Date of the Settlement, Lead Plaintiff and Defendants shall expressly waive, and each of the other Class Members shall be deemed to have waived, and by operation of the Judgment or the Alternate Judgment, if applicable, shall have expressly waived, any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law or foreign law, that is similar, comparable, or equivalent to California Civil Code §1542, which provides:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.

Lead Plaintiff and Defendants acknowledge, and each of the other Class Members shall be deemed by operation of law to have acknowledged, that the foregoing waiver was separately bargained for and is a key element of the Settlement.

- 46. The Judgment will also provide that, upon the Effective Date of the Settlement, Defendants' Releasees, on behalf of themselves, and their respective heirs, executors, administrators, predecessors, successors, and assigns in their capacities as such, will have fully, finally, and forever compromised, settled, released, resolved, relinquished, waived, and discharged any and all Released Defendants' Claims (as defined in ¶47 below) against Lead Plaintiff and the other Plaintiff's Releasees (as defined in ¶48 below), and will forever be barred and enjoined from prosecuting any and all Released Defendants' Claims against any of the Plaintiff's Releasees. This Release will not apply to any of the Excluded Defendants' Claims (as defined in ¶47 below).
- 47. "Released Defendants' Claims" means any and all manner of claims, demands, rights, liabilities, losses, obligations, duties, damages, costs, debts, expenses, interest, penalties, sanctions, fees, attorneys' fees, actions, potential actions, causes of action, suits, judgments, defenses, counterclaims, offsets, decrees, matters, issues and controversies of any kind, nature or description whatsoever, whether disclosed or undisclosed, accrued or unaccrued, apparent or not apparent, foreseen or unforeseen, matured or not matured, suspected or unsuspected, liquidated or not liquidated, fixed or contingent, including both known and Unknown Claims, that were or could have been asserted by any of the Defendants in any court, tribunal, forum or proceeding, whether based on state, local, foreign, federal, statutory, regulatory, common, or other law or rule, and that are based upon, arise out of, or relate to the commencement, prosecution, defense, mediation or settlement of the Action, including, but not limited to, discovery produced in the Action; provided, however, for the avoidance of doubt, that the Released Defendants' Claims shall not include any claims to

enforce the Stipulation, the Settlement, or the Judgment. Released Defendants' Claims do not include any of the following claims: (i) claims relating to the enforcement of the Settlement; (ii) claims against the persons and entities who submitted a request for exclusion from the Class in connection with the Class Notice; or (iii) claims against persons or entities who submit a request for exclusion from the Class in connection with this Notice ("Excluded Defendants' Claims").

48. "Plaintiff's Releasees" means Lead Plaintiff, all other plaintiffs in the Action, all other Class Members, and Plaintiff's Counsel, and their respective current and former parents, affiliates, subsidiaries, officers, directors, agents, successors, predecessors, assigns, assignees, partnerships, partners, trustees, trusts, employees, immediate family members, insurers, reinsurers, and attorneys, in their capacities as such.

HOW DO I PARTICIPATE IN THE SETTLEMENT? WHAT DO I NEED TO DO?

49. To be eligible for a payment from the Settlement, you must be a member of the Class and you must timely complete and return the Claim Form with adequate supporting documentation *postmarked* (if mailed), or submitted online at www.OvaScienceSecuritiesLitigation.com, no later than August 22, 2022. A Claim Form is included with this Notice, or you may obtain one from the website maintained by the Claims Administrator for the Settlement, www.OvaScienceSecuritiesLitigation.com. You may also request that a Claim Form be mailed to you by calling the Claims Administrator toll-free at 1-866-757-7818 or by emailing the Claims Administrator at info@OvaScienceSecuritiesLitigation.com. Please retain all records of your ownership of and transactions in OvaScience common stock, as they will be needed to document your Claim. The Parties and Claims Administrator do not have information about your transactions in OvaScience common stock. If you do not submit a timely and valid Claim Form, you will not be eligible to share in the Net Settlement Fund.

HOW MUCH WILL MY PAYMENT BE?

- 50. At this time, it is not possible to make any determination as to how much any individual Class Member may receive from the Settlement.
- 51. Pursuant to the Settlement, Defendants have agreed to pay or caused to be paid a total of \$15,000,000 in cash (the "Settlement Amount"). The Settlement Amount will be deposited into an escrow account. The Settlement Amount plus any interest earned thereon is referred to as the "Settlement Fund." If the Settlement is approved by the Court and the Effective Date occurs, the Net Settlement Fund will be distributed to Class Members who submit valid Claim Forms, in accordance with the proposed Plan of Allocation or such other plan of allocation as the Court may approve.
- 52. The Net Settlement Fund will not be distributed unless and until the Court has approved the Settlement and a Plan of Allocation and that decision is affirmed on appeal (if any) and/or the time for any petition for rehearing, appeal, or review, whether by certiorari or otherwise, has expired.
- 53. Neither Defendants nor any other person or entity that paid any portion of the Settlement Amount on their behalf are entitled to get back any portion of the Settlement Fund once the Court's order or judgment approving the Settlement becomes final. Defendants will not have any liability, obligation, or responsibility for the administration of the Settlement, the disbursement of the Net Settlement Fund, or the Plan of Allocation.
- 54. Approval of the Settlement is independent from approval of a plan of allocation. Any determination with respect to a plan of allocation will not affect the Settlement, if approved.
- 55. Unless the Court otherwise orders, any Class Member who or that fails to submit a Claim Form postmarked (if mailed), or submitted online, on or before August 22, 2022 shall be fully and forever barred from receiving payments pursuant to the Settlement but will in all other respects remain a member of the Class and be subject to the provisions of the Stipulation, including the terms of any Judgment entered and the releases given. This means that each Class Member releases the Released Plaintiff's Claims (as defined in ¶43 above) against the Defendants' Releasees (as defined in ¶44 above) and will be barred and enjoined from prosecuting any of the Released Plaintiff's Claims against any of the Defendants' Releasees whether or not such Class Member submits a Claim Form.
- 56. Participants in and beneficiaries of any employee retirement and/or benefit plan ("Employee Plan") should NOT include any information relating to their transactions in OvaScience common stock held through the Employee Plan in any Claim Form that they submit in this Action. Claims based on any Employee Plan's transactions in OvaScience common stock may be made by the plan itself.
- 57. The Court has reserved jurisdiction to allow, disallow, or adjust on equitable grounds the Claim of any Class Member. Each Claimant shall be deemed to have submitted to the jurisdiction of the Court with respect to his, her, or its Claim Form.
- 58. Only members of the Class will be eligible to share in the distribution of the Net Settlement Fund. Persons and entities that are excluded from the Class by definition or that excluded themselves from the Class pursuant to request will not be eligible for a payment and should not submit Claim Forms. The only security that is included in the Settlement is OvaScience common stock.

59. Appendix A to this Notice sets forth the Plan of Allocation for allocating the Net Settlement Fund among Authorized Claimants, as proposed by Lead Plaintiff. At the Settlement Hearing, Lead Plaintiff will request that the Court approve the Plan of Allocation. The Court may modify the Plan of Allocation, or approve a different plan of allocation, without further notice to the Class.

HOW DO I EXCLUDE MYSELF FROM THE CLASS AND THE PROPOSED SETTLEMENT?

- 60. If you do not want to receive a payment from the Settlement, or you want to keep the right to potentially sue Defendants or any other Defendants' Releasees, on your own, about the claims being released by the Settlement, then you must take steps to remove yourself from the Settlement. This is called excluding yourself or is sometimes referred to as "opting out." If you are requesting exclusion because you want to bring your own lawsuit based on the matters alleged in this litigation, you may want to consult an attorney and discuss whether any individual claim that you may wish to pursue would be time-barred by the applicable statutes of limitation or repose. IF YOU HAVE PREVIOUSLY SUBMITTED A REQUEST FOR EXCLUSION, YOU DO NOT HAVE TO DO SO AGAIN.
- 61. To exclude yourself from the Class and the Settlement, you must send a signed and dated letter by mail stating that you "request exclusion from the Class in the *OvaScience Securities Litigation*." Your letter must include your purchases or acquisitions of shares of OvaScience common stock during the Class Period, including the date(s), the number of shares of OvaScience common stock purchased or acquired, and the price(s) paid for each such purchase or acquisition. In addition, you must include your name, address, telephone number, and your signature. You must submit your exclusion request so that it is postmarked no later than July 5, 2022, to:

OvaScience Securities Litigation c/o Gilardi & Co. LLC EXCLUSIONS 150 Royall Street, Suite 101 Canton, MA 02021

You cannot exclude yourself by phone or by email. If you make a proper request for exclusion, you will not receive a settlement payment, and you cannot object to the Settlement. If you make a proper request for exclusion, you will not be legally bound by anything that happens in the lawsuit.

WHAT PAYMENT ARE THE ATTORNEYS FOR THE CLASS SEEKING? HOW WILL THE LAWYERS BE PAID?

62. Plaintiff's Counsel have not received any payment for their services in pursuing claims against Defendants on behalf of the Class, nor have Plaintiff's Counsel been paid for their Litigation Expenses. Lead Counsel will apply to the Court for an immediate award of attorneys' fees on behalf of all Plaintiff's Counsel in an amount not to exceed 33-1/3% of the Settlement Fund, plus interest, to be paid at the time of award by the Court. At the same time, Lead Counsel also intends to apply for payment of Plaintiff's Counsel's Litigation Expenses from the Settlement Fund in an amount not to exceed \$875,000, plus interest, which amount may include an application for reimbursement of the reasonable costs and expenses incurred by Lead Plaintiff directly related to its representation of the Class, not to exceed \$15,000, pursuant to the PSLRA. The Court will determine the amount of any award of attorneys' fees or Litigation Expenses. Any award of attorneys' fees and Litigation Expenses, including any reimbursement of costs and expenses to Lead Plaintiff, will be paid from the Settlement Fund at the time of award by the Court and prior to allocation and payment to Authorized Claimants. *Class Members are not personally liable for any such fees or expenses.*

WHEN AND WHERE WILL THE COURT DECIDE WHETHER TO APPROVE THE SETTLEMENT? DO I HAVE TO COME TO THE HEARING? MAY I SPEAK AT THE HEARING IF I DON'T LIKE THE SETTLEMENT?

- 63. Class Members do not need to attend the Settlement Hearing. The Court will consider any submission made in accordance with the provisions below even if a Class Member does not attend the hearing. You can participate in the Settlement without attending the Settlement Hearing.
- 64. Please Note: The date and time of the Settlement Hearing may change without further written notice to the Class. In addition, the ongoing Covid-19 health emergency is a fluid situation that creates the possibility that the Court may decide to conduct the Settlement Hearing by video or telephonic conference, or otherwise allow Class Members to appear at the hearing by phone or video, without further written notice to the Class. In order to determine whether the date and time of the Settlement Hearing have changed, or whether Class Members must or may participate by phone or video, it is important that you monitor the Court's docket and the case website, www.OvaScienceSecuritiesLitigation.com, before making any plans to attend the Settlement Hearing. Any updates regarding the hearing, including any changes to the date or time of the hearing or updates regarding in-person or telephonic appearances at the hearing, will be posted to the case website, www.OvaScienceSecuritiesLitigation.com. Also, if the Court requires or allows Class Members to participate in the Settlement Hearing by telephone or video conference, the information needed to access the conference will be posted to www.OvaScienceSecuritiesLitigation.com.

- 65. The Settlement Hearing will be held on **July 26, 2022 at 2:45 p.m.**, before the Honorable Indira Talwani either in person at the United States District Court for the District of Massachusetts, John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, MA 02210, or by telephone or videoconference (in the discretion of the Court). At the hearing, the Court will, among other things, (i) determine whether the proposed Settlement on the terms and conditions provided for in the Stipulation is fair, reasonable, and adequate to the Class, and should be finally approved by the Court; (ii) determine whether the Action should be dismissed with prejudice against Defendants, and the Releases specified and described in the Stipulation (and in this Notice) should be granted; (iii) determine whether the proposed Plan of Allocation should be approved as fair and reasonable; (iv) determine whether Lead Counsel's motion for attorneys' fees and Litigation Expenses (including an award to the Lead Plaintiff) should be approved; and (v) consider any other matters that may properly be brought before the Court in connection with the Settlement. The Court reserves the right to approve the Settlement, the Plan of Allocation, and Lead Counsel's motion for attorneys' fees and Litigation Expenses, and/or consider any other matter related to the Settlement at or after the Settlement Hearing without further notice to the members of the Class.
- 66. Any Class Member may object to the Settlement, the proposed Plan of Allocation, or Lead Counsel's motion for attorneys' fees and Litigation Expenses. Objections must be in writing. To object, you must file any written objection, together with copies of all other papers and briefs supporting the objection, with the Clerk's Office at the United States District Court for the District of Massachusetts at the address set forth below, as well as serve copies on Lead Counsel and Defendants' Counsel at the addresses set forth below, *such that they are received no later than July 5, 2022*.

Clerk's Office

United States District Court
District of Massachusetts
John Joseph Moakley U.S.
Courthouse, 1 Courthouse Way
Boston, MA 02210

Lead Counsel

Robbins Geller Rudman & Dowd LLP Ellen Gusikoff Stewart, Esq. 655 West Broadway Suite 1900 San Diego, CA 92101

Counsel for OvaScience Defendants and Richard Aldrich

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. John F. Sylvia, Esq. One Financial Center Boston, MA 02111

Counsel for Longwood Fund, L.P. and Longwood Fund, GP, LLC

Prince Lobel Tye LLP Joseph P. Curtin, Esq. One International Place Suite 3700 Boston, MA 02110

- 67. Any objections, filings, and other submissions by the objecting Class Member must identify the case name and civil action number, Dahhan v. OvaScience, Inc., et al., No. 1:17-cv-10511-IT, and they must (i) state the name, address, and telephone number of the person or entity objecting and must be signed by the objector (even if the objector is represented by counsel); (ii) state whether the objector is represented by counsel and, if so, the name, address, and telephone number of the objector's counsel; (iii) state with specificity the grounds for the Class Member's objection, including any legal and evidentiary support the Class Member wishes to bring to the Court's attention and whether the objection applies only to the objector, to a specific subset of the Class, or to the entire Class; and (iv) include documents sufficient to prove membership in the Class, including documents showing the number of shares of OvaScience common stock that the objecting Class Member: (A) owned as of the opening of trading on December 17, 2014, and (B) purchased or acquired and/or sold during the Class Period (i.e., between December 17, 2014 and September 28, 2015, inclusive), including the dates, number of OvaScience shares, and prices of each such purchase, acquisition, and sale. Documentation establishing membership in the Class must consist of copies of brokerage confirmation slips or monthly brokerage account statements, or an authorized statement from the objector's broker containing the transactional and holding information found in a broker confirmation slip or account statement. You may not object to the Settlement, the Plan of Allocation, or Lead Counsel's motion for attorneys' fees and Litigation Expenses if you previously excluded yourself from the Class or if you are not a member of the Class.
- 68. You may file a written objection without having to appear at the Settlement Hearing. You may not, however, appear at the Settlement Hearing to present your objection unless you first file a written objection in accordance with the procedures described above, unless the Court orders otherwise.
- 69. If you wish to be heard orally at the hearing in opposition to the approval of the Settlement, the Plan of Allocation, or Lead Counsel's motion for attorneys' fees and Litigation Expenses, assuming you timely file a written objection as described above, you must also file a notice of appearance with the Clerk's Office and serve it on Lead Counsel and on Defendants' Counsel at the addresses set forth in ¶66 above so that it is **received** on or before July 5, 2022. Persons who intend to object and desire to present evidence at the Settlement Hearing must include in their written objection or notice of appearance the identity of any witnesses they may call to testify and exhibits they intend

to introduce into evidence at the hearing. Objectors who intend to appear at the Settlement Hearing through counsel must also identify that counsel by name, address, and telephone number. It is within the Court's discretion to allow appearances at the Settlement Hearing either in person or by telephone or videoconference, with or without the filing of written objections.

- 70. You are not required to hire an attorney to represent you in making written objections or in appearing at the Settlement Hearing. However, if you decide to hire an attorney, it will be at your own expense, and that attorney must file a notice of appearance with the Court and serve it on Lead Counsel and Defendants' Counsel at the addresses set forth in ¶66 above so that the notice is *received* on or before July 5, 2022.
- 71. The Settlement Hearing may be adjourned by the Court without further written notice to the Class. If you intend to attend the Settlement Hearing, you should confirm the date and time of the hearing as stated in ¶65 above.
- 72. Unless the Court orders otherwise, any Class Member who does not object in the manner described above will be deemed to have waived any objection and shall be forever foreclosed from making any objection to the proposed Settlement, the proposed Plan of Allocation, or Lead Counsel's motion for attorneys' fees and Litigation Expenses. Class Members do not need to appear at the Settlement Hearing or take any other action to indicate their approval.

WHAT IF I BOUGHT OVASCIENCE STOCK ON SOMEONE ELSE'S BEHALF?

- 73. If you previously provided the names and addresses of persons and entities on whose behalf you purchased or acquired OvaScience common stock during the period between December 17, 2014 and September 28, 2015, inclusive, in connection with the Class Notice (disseminated in or around July 2020) and (i) those names and addresses remain current and (ii) you have no additional names and addresses for potential Class Members to provide to the Claims Administrator, you need do nothing further at this time. The Claims Administrator will mail a copy of this Notice and the Claim Form (the "Settlement Notice Packet") to the beneficial owners whose names and addresses were previously provided in connection with the Class Notices.
- 74. If you elected to mail the Class Notice directly to beneficial owners, you were advised that you must retain the mailing records for use in connection with any further notices that may be provided in the Action. If you elected this option, the Claims Administrator will forward the same number of Settlement Notice Packets to you to send to the beneficial owners. You must mail the Settlement Notice Packets to the beneficial owners no later than seven (7) calendar days after your receipt of them.
- 75. If you have additional name and address information, the name and address information of certain of your beneficial owners has changed, or if you need additional copies of the Settlement Notice Packet, or have not already provided information regarding persons and entities on whose behalf you purchased or acquired OvaScience common stock during the period between December 17, 2014 and September 28, 2015, inclusive, in connection with the Class Notice, the Court has ordered that, within seven (7) calendar days of receipt of this Notice, you must either: (i) send a list of the names and addresses of such beneficial owners to the Claims Administrator at notifications@gilardi.com or *OvaScience Securities Litigation*, c/o Gilardi & Co. LLC, P.O. Box 43312, Providence, RI 02940-3312, in which event the Claims Administrator shall promptly mail the Settlement Notice Packet to such beneficial owners; or (ii) request from the Claims Administrator sufficient copies of the Settlement Notice Packet to forward to all such beneficial owners, which you must then mail to the beneficial owners by First Class Mail no later than seven (7) calendar days after receipt. As stated above, if you have already provided this information in connection with the Class Notice, unless that information has changed (e.g., the beneficial owner has changed address), it is unnecessary to provide such information again.
- 76. Upon full and timely compliance with these directions, such nominees may seek reimbursement of their reasonable expenses actually incurred, by providing the Claims Administrator with proper documentation supporting the expenses for which reimbursement is sought. Copies of this Notice and the Claim Form may also be obtained from the case website, www.OvaScienceSecuritiesLitigation.com, by calling the Claims Administrator toll-free at 1-866-757-7818, or by emailing the Claims Administrator at info@OvaScienceSecuritiesLitigation.com.

CAN I SEE THE COURT FILE? WHOM SHOULD I CONTACT IF I HAVE QUESTIONS?

77. This Notice contains only a summary of the terms of the proposed Settlement. For the precise terms and conditions of the Settlement or to obtain additional information, you may find the Stipulation and other relevant documents at www.OvaScienceSecuritiesLitigation.com, by contacting Lead Counsel or the Claims Administrator at the addresses below, by accessing the Court docket in this case, for a fee, through the Court's Public Access to Court Electronic Records (PACER) system at https://ecf.mad.uscourts.gov, or by visiting, during regular office hours, the Office of the Clerk, John Joseph Moakley U.S. Courthouse, 1 Courthouse Way, Boston, MA 02210. Additionally, copies of any related orders entered by the Court and certain other filings in this Action will be posted on the case website, www.OvaScienceSecuritiesLitigation.com.

Case 1:17-cv-10511-IT Document 187-1 Filed 06/21/22 Page 13 of 23

All inquiries concerning this Notice and the Claim Form should be directed to:

OvaScience Securities Litigation
c/o Gilardi & Co. LLC
P.O. Box 43312
Providence, RI 02940-3312
1-866-757-7818
info@OvaScienceSecuritiesLitigation.com
www.OvaScienceSecuritiesLitigation.com

and/or

Ellen Gusikoff Stewart, Esq.
Robbins Geller Rudman & Dowd LLP
655 West Broadway, Suite 1900
San Diego, CA 92101
1-800-449-4900
elleng@rgrdlaw.com

DO NOT CALL OR WRITE THE COURT, THE OFFICE OF THE CLERK OF THE COURT, DEFENDANTS, OR THEIR COUNSEL REGARDING THIS SETTLEMENT OR THE CLAIM PROCESS.

Dated: April 1, 2022

By Order of the Court

United States District Court

District of Massachusetts

APPENDIX A PROPOSED PLAN OF ALLOCATION OF THE NET SETTLEMENT FUND

- 1. As discussed above, the Settlement provides \$15,000,000 in cash for the benefit of the Class. The Settlement Amount and any interest it earns constitute the "Settlement Fund." The Settlement Fund, after deduction of Court-approved attorneys' fees and expenses, Notice and Administration Costs, Taxes, and any other fees or expenses approved by the Court, is the "Net Settlement Fund." If the Settlement is approved by the Court, the Net Settlement Fund will be distributed to eligible Authorized Claimants members of the Class who timely submit valid Claim Forms that are accepted for payment by the Court in accordance with this proposed Plan of Allocation ("Plan of Allocation" or "Plan") or such other plan of allocation as the Court may approve. Class Members who do not timely submit valid Claim Forms will not share in the Net Settlement Fund, but will otherwise be bound by the Settlement. The Court may approve this proposed Plan of Allocation, or modify it, without additional notice to the Class. Any order modifying the Plan of Allocation will be posted on the Settlement website: www.OvaScienceSecuritiesLitigation.com.
- 2. The objective of the Plan of Allocation is to distribute the Settlement proceeds equitably among those Class Members who suffered economic losses as a proximate result of the alleged wrongdoing. The Plan of Allocation is not a formal damage analysis, and the calculations made in accordance with the Plan of Allocation are not intended to be estimates of, or indicative of, the amounts that Class Members might have been able to recover after a trial. Nor are the calculations in accordance with the Plan of Allocation intended to be estimates of the amounts that will be paid to Authorized Claimants under the Settlement. The computations under the Plan of Allocation are only a method to weigh, in a fair and equitable manner, the claims of Authorized Claimants against one another for the purpose of making *pro rata* allocations of the Net Settlement Fund.
- 3. The Plan of Allocation was developed in consultation with Lead Plaintiff's damages expert. In developing the Plan of Allocation, Lead Plaintiff's damages expert calculated the estimated amount of alleged artificial inflation in the price of OvaScience common stock that was allegedly proximately caused by Defendants' alleged materially false and misleading statements and omissions. In calculating the estimated artificial inflation allegedly caused by those misrepresentations and omissions, Lead Plaintiff's damages expert considered price changes in OvaScience common stock in reaction to public disclosures that allegedly corrected the respective alleged misrepresentations and omissions, adjusting the price change for factors that were attributable to market, industry, and for non-fraud related Company-specific information.
- 4. In order to have recoverable damages under the federal securities laws, disclosure of the alleged misrepresentation and/or omission must be the cause of the decline in the price of the security. In this Action, Lead Plaintiff alleges that corrective information (referred to as a "corrective disclosure") was released to the market on March 26-27, 2015; March 30, 2015; April 6-7, 2015; June 17-18, 2015; August 28, 2015; and September 29-30, 2015.
- 5. In order to have a "Recognized Loss Amount" under the Plan of Allocation, OvaScience common stock must have been purchased or acquired during the Class Period and held through at least one corrective disclosure.³

CALCULATION OF RECOGNIZED LOSS AMOUNTS

- 6. Based on the formula stated below, a "Recognized Loss Amount" will be calculated for each purchase or acquisition of OvaScience common stock during the Class Period that is listed on the Claim Form and for which adequate documentation is provided. If a Recognized Loss Amount calculates to a negative number or zero under the formula below, that Recognized Loss Amount will be zero.
- 7. For each share of OvaScience common stock purchased or acquired from December 17, 2014 through September 28, 2015, inclusive, and:
 - (a) Sold prior to March 26, 2015, the Recognized Loss Amount will be \$0.00;
- (b) Sold from March 26, 2015 through and including the close of trading on September 29, 2015, the Recognized Loss Amount will be **the lesser of**: (i) the amount of artificial inflation per share on the date of the purchase or acquisition as stated in Table A minus the amount of artificial inflation per share on the date of sale as stated in Table A, or (ii) the purchase or acquisition price minus the sale price; and
- (c) Sold from September 30, 2015 through and including the close of trading on December 28, 2015, the Recognized Loss Amount will be *the least of*: (i) the difference between artificial inflation at purchase (see Table A below) and the artificial inflation at sale (see Table A below), (ii) the purchase or acquisition price minus the sale price, or (iii) the purchase or acquisition price minus the average closing price between September 30, 2015 and the date of sale as stated in Table B: and
- (d) Held as of the close of trading on December 28, 2015, the Recognized Loss Amount will be *the lesser of*: (i) the artificial inflation at purchase (see Table A below), or (ii) the purchase or acquisition price minus \$11.30, the average closing price for OvaScience common stock between September 30, 2015 and December 28, 2015 (the last entry in Table B below).⁴

³ Any transactions in OvaScience stock executed outside regular trading hours for the U.S. financial markets shall be deemed to have occurred during the next trading session.

Under Section 21(D)(e)(1) of the Exchange Act, "in any private action arising under this Act in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that

TABLE A
Estimated Artificial Inflation in OvaScience Common Stock

Date Range	Artificial Inflation Per Share
December 17, 2014 through March 25, 2015	\$31.91
March 26, 2015	\$30.51
March 27, 2015 through March 29, 2015	\$24.50
March 30, 2015 through April 5, 2015	\$18.72
April 6, 2015	\$17.33
April 7, 2015 through June 16, 2015	\$13.08
June 17, 2015	\$10.77
June 18, 2015 through August 27, 2015	\$8.12
August 28, 2015 through September 28, 2015	\$6.45
September 29, 2015	\$0.59
September 30, 2015 and later	\$0.00

TABLE B

OvaScience Closing Price and Average Closing Price
September 30, 2015 – December 28, 2015

		Average Price			Average Price
		Between			Between
	Closing	9/30/2015 and		Closing	9/30/2015 and
Date	Price	Date Shown	Date	Price	Date Shown
9/30/2015	\$8.49	\$8.49	11/12/2015	\$9.94	\$12.32
10/1/2015	\$9.47	\$8.98	11/13/2015	\$9.87	\$12.25
10/2/2015	\$10.25	\$9.40	11/16/2015	\$10.54	\$12.20
10/5/2015	\$10.95	\$9.79	11/17/2015	\$10.94	\$12.16
10/6/2015	\$10.83	\$10.00	11/18/2015	\$11.00	\$12.13
10/7/2015	\$11.28	\$10.21	11/19/2015	\$10.93	\$12.09
10/8/2015	\$11.25	\$10.36	11/20/2015	\$10.79	\$12.06
10/9/2015	\$12.25	\$10.60	11/23/2015	\$10.72	\$12.03
10/12/2015	\$12.18	\$10.77	11/24/2015	\$10.59	\$11.99
10/13/2015	\$10.73	\$10.77	11/25/2015	\$10.20	\$11.95
10/14/2015	\$11.13	\$10.80	11/27/2015	\$10.00	\$11.90
10/15/2015	\$12.36	\$10.93	11/30/2015	\$9.43	\$11.84
10/16/2015	\$12.99	\$11.09	12/1/2015	\$9.77	\$11.80
10/19/2015	\$14.73	\$11.35	12/2/2015	\$10.31	\$11.76
10/20/2015	\$14.03	\$11.53	12/3/2015	\$9.81	\$11.72
10/21/2015	\$14.41	\$11.71	12/4/2015	\$10.10	\$11.69
10/22/2015	\$13.71	\$11.83	12/7/2015	\$9.25	\$11.63
10/23/2015	\$14.02	\$11.95	12/8/2015	\$9.37	\$11.59
10/26/2015	\$13.67	\$12.04	12/9/2015	\$9.50	\$11.55
10/27/2015	\$14.50	\$12.16	12/10/2015	\$10.39	\$11.52
10/28/2015	\$14.32	\$12.26	12/11/2015	\$9.44	\$11.48
10/29/2015	\$13.92	\$12.34	12/14/2015	\$9.47	\$11.45
10/30/2015	\$12.97	\$12.37	12/15/2015	\$10.42	\$11.43
11/2/2015	\$14.00	\$12.44	12/16/2015	\$10.67	\$11.41
11/3/2015	\$14.05	\$12.50	12/17/2015	\$10.33	\$11.39
11/4/2015	\$14.17	\$12.56	12/18/2015	\$10.45	\$11.38
11/5/2015	\$13.13	\$12.58	12/21/2015	\$10.23	\$11.36
11/6/2015	\$12.23	\$12.57	12/22/2015	\$10.50	\$11.34
11/9/2015	\$11.06	\$12.52	12/23/2015	\$11.05	\$11.34
11/10/2015	\$11.04	\$12.47	12/24/2015	\$10.54	\$11.33
11/11/2015	\$10.16	\$12.40	12/28/2015	\$9.84	\$11.30

is the basis for the action is disseminated to the market." Consistent with the requirements of the statute, Recognized Loss Amounts are reduced to an appropriate extent by taking into account the closing prices of OvaScience common stock during the "90-day lookback period," September 30, 2015 through and including December 28, 2015. The mean (average) closing price for OvaScience common stock during this 90-day look-back period was \$11.30.

ADDITIONAL PROVISIONS

- 8. Given the costs of distribution, the Net Settlement Fund will be allocated among all Authorized Claimants whose Distribution Amount (defined in ¶11 below) is \$10.00 or greater.
- 9. If a claimant has more than one purchase or acquisition or sale of OvaScience common stock during the Class Period, purchases and sales will be matched on a First In, First Out ("FIFO") basis. Class Period sales will be matched first against any holdings at the beginning of the Class Period, and then against purchases or acquisitions in chronological order, beginning with the earliest purchase or acquisition made during the Class Period.
- 10. A claimant's "Recognized Claim" under the Plan of Allocation will be the sum of his, her, or its Recognized Loss Amounts as calculated under ¶7 above.
- 11. The Net Settlement Fund will be distributed to Authorized Claimants on a *pro rata* basis, based on the relative size of their Recognized Claims. Specifically, a "Distribution Amount" will be calculated for each Authorized Claimant, which will be the Authorized Claimant's Recognized Claim divided by the total Recognized Claims of all Authorized Claimants, multiplied by the total amount in the Net Settlement Fund. If any Authorized Claimant's Distribution Amount calculates to less than \$10.00, it will not be included in the calculation and no distribution will be made to that Authorized Claimant.
- 12. For the purposes of calculations in ¶7 above, "purchase price" means the actual price paid, excluding commissions and other charges, and "sale price" means the actual price received, not deducting commissions and other charges.
- 13. Purchases, acquisitions and sales of OvaScience common stock will be deemed to have occurred on the "contract" or "trade" date as opposed to the "settlement" or "payment" date. The receipt or grant by gift, inheritance, or operation of law of OvaScience common stock during the Class Period will not be deemed a purchase, acquisition or sale of OvaScience common stock for the calculation of an Authorized Claimant's Recognized Loss Amount, nor will the receipt or grant be deemed an assignment of any claim relating to the purchase or acquisition of OvaScience common stock unless: (i) the donor or decedent purchased or acquired the common stock during the Class Period; (ii) no Claim Form was submitted by or on behalf of the donor, on behalf of the decedent, or by anyone else with respect to those shares; and (iii) it is specifically so provided in the instrument of gift or assignment.
- 14. The date of covering a "short sale" is deemed to be the date of purchase of the OvaScience common stock. The date of a "short sale" is deemed to be the date of sale of the OvaScience common stock. Under the Plan of Allocation, however, the Recognized Loss Amount on "short sales" is zero. In the event that a claimant has an opening short position in OvaScience common stock, his, her, or its earliest Class Period purchases of OvaScience common stock will be matched against the opening short position, and not be entitled to a recovery, until that short position is fully covered.
- 15. Option contracts are not securities eligible to participate in the Settlement. With respect to OvaScience common stock purchased, acquired or sold through the exercise or assignment of an option, the purchase/sale date of the OvaScience common stock is the exercise/assignment date of the option and the purchase/sale price of the OvaScience common stock is the exercise/assignment price of the option.
- 16. If a claimant had a market gain with respect to his, her, or its overall transactions in OvaScience common stock during the Class Period, the value of the claimant's Recognized Claim will be zero. If a claimant suffered an overall market loss with respect to his, her, or its overall transactions in OvaScience common stock during the Class Period but that market loss was less than the claimant's total Recognized Claim calculated above, then the claimant's Recognized Claim will be limited to the amount of the actual market loss. For purposes of determining whether a claimant had a market gain with respect to his, her, or its overall transactions in OvaScience common stock during the Class Period or suffered a market loss, the Claims Administrator will determine the difference between (i) the claimant's Total Purchase Amount⁵ and (ii) the sum of the claimant's Total Sales Proceeds⁶ and Holding Value.⁷ This difference will be deemed a claimant's market gain (if the difference is a negative number or zero) or the claimant's market loss (if the difference is a positive number) with respect to his, her, or its overall transactions in OvaScience common stock during the Class Period.

The "Total Purchase Amount" will be the total amount the claimant paid (excluding commissions and other charges) for OvaScience common stock purchased or acquired during the Class Period.

The Claims Administrator will match any sales of OvaScience common stock during the Class Period first against the claimant's opening position (the proceeds of those sales will not be considered for purposes of calculating market gains or losses). The total amount received (not deducting commissions and other charges) for the remaining sales of OvaScience common stock sold during the Class Period will be the "Total Sales Proceeds."

The Claims Administrator will ascribe a "Holding Value" of \$11.30 per share for OvaScience common stock purchased or acquired during the Class Period and still held as of the close of trading on September 28, 2015.

Case 1:17-cv-10511-IT Document 187-1 Filed 06/21/22 Page 17 of 23

- 17. After the initial distribution of the Net Settlement Fund, the Claims Administrator will make reasonable and diligent efforts to have Authorized Claimants cash their distribution checks. To the extent any monies remain in the Net Settlement Fund after the initial distribution, if Lead Counsel, in consultation with the Claims Administrator, determine that it is cost-effective to do so, the Claims Administrator, no less than nine (9) months after the initial distribution, will conduct a re-distribution of the funds remaining after payment of any unpaid fees and expenses incurred in administering the Settlement, including for such re-distribution, to Authorized Claimants who have cashed their initial distributions and who would receive at least \$10.00 from such re-distribution. Additional re-distributions to Authorized Claimants who have cashed their prior checks may occur thereafter if Lead Counsel, in consultation with the Claims Administrator, determine that additional re-distributions, after the deduction of any additional fees and expenses incurred in administering the Settlement, including for such re-distributions, would be cost-effective. At such time as it is determined that the re-distribution of funds remaining in the Net Settlement Fund is not cost-effective, the remaining balance shall be contributed to non-sectarian, not-for-profit organization(s), to be recommended by Lead Counsel and approved by the Court.
- 18. Payment pursuant to the Plan of Allocation, or such other plan of allocation as may be approved by the Court, shall be conclusive against all Authorized Claimants. No person shall have any claim against Lead Plaintiff, Plaintiff's Counsel, Lead Plaintiff's damages expert, Defendants, Defendants' Counsel, any of the other Plaintiff's Releasees or Defendants' Releasees, or the Claims Administrator or other agent designated by Lead Counsel arising from distributions made substantially in accordance with the Stipulation, the Plan of Allocation approved by the Court, or further orders of the Court. Lead Plaintiff, Defendants, and their respective counsel, and all other Defendants' Releasees, shall have no responsibility or liability whatsoever for the investment or distribution of the Settlement Fund or the Net Settlement Fund; the Plan of Allocation; the determination, administration, calculation, or payment of any Claim or nonperformance of the Claims Administrator; the payment or withholding of Taxes; or any losses incurred in connection therewith.
- 19. The Plan of Allocation stated herein is the plan that is being proposed to the Court for its approval by Lead Plaintiff after consultation with its damages expert. The Court may approve this Plan of Allocation as proposed or it may modify the Plan without further notice to the Class. Any Orders regarding any modification of the Plan of Allocation will be posted on the case website, www.OvaScienceSecuritiesLitigation.com.

Case 1:17-cv-10511-IT Document 187-1 Filed 06/21/22 Page 18 of 23

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

FADI DAHHAN, Individually a Others Similarly Situated,	nd on Behalf of All) No. 1:17-cv-10511-IT
	Plaintiff,) <u>OLAGO AGTICIV</u>)
VS.)
OVASCIENCE, INC., et al.,)
	Defendants.	,))

PROOF OF CLAIM AND RELEASE FORM

1. To be eligible to receive a share of the Net Settlement Fund in connection with the Settlement of this Action, you must complete and sign this Proof of Claim and Release Form ("Claim Form") and mail it by first-class mail to the address below, or submit it online at www.OvaScienceSecuritiesLitigation.com, with supporting documentation, postmarked (if mailed) or received (if submitted online) by no later than August 22, 2022.

Mail to:

OvaScience Securities Litigation c/o Gilardi & Co. LLC P.O. Box 43312 Providence, RI 02940-3312

Failure to submit your Claim Form by the date specified will subject your claim to rejection and may preclude you from being eligible to receive a payment from the Settlement.

2. Do not mail or deliver your Claim Form to the Court, Lead Counsel, Defendants' Counsel, or any of the Parties to the Action. Submit your Claim Form only to the Claims Administrator at the address set forth above.

GENERAL INSTRUCTIONS

- 3. It is important that you completely read and understand the Notice of (I) Proposed Settlement and Plan of Allocation; (II) Settlement Hearing; and (III) Motion for Attorneys' Fees and Litigation Expenses (the "Notice") that accompanies this Claim Form, including the proposed Plan of Allocation of the Net Settlement Fund set forth in the Notice. The Notice describes the proposed Settlement, how Class Members are affected by the Settlement, and the manner in which the Net Settlement Fund will be distributed if the Settlement and Plan of Allocation are approved by the Court. The Notice also contains the definitions of many of the defined terms (which are indicated by initial capital letters) used in this Claim Form. By signing and submitting this Claim Form, you will be certifying that you have read and that you understand the Notice, including the terms of the releases described therein and provided for herein.
- 4. This Claim Form is directed to all persons or entities who purchased or acquired common stock of OvaScience, Inc. ("OvaScience") between December 17, 2014 and September 28, 2015, inclusive (the "Class Period") (the "Class").
- 5. By submitting this Claim Form, you will be making a request to share in the proceeds of the Settlement described in the Notice. IF YOU ARE NOT A MEMBER OF THE CLASS (see the definition of the Class in Paragraph 34 of the Notice, which states who is included in and who is excluded from the Class), DO NOT SUBMIT A CLAIM FORM; **YOU MAY NOT, DIRECTLY OR INDIRECTLY, PARTICIPATE IN THE SETTLEMENT**. THUS, IF YOU ARE EXCLUDED FROM THE CLASS, ANY CLAIM FORM THAT YOU SUBMIT, OR THAT MAY BE SUBMITTED ON YOUR BEHALF, WILL NOT BE ACCEPTED.
- 6. Submission of this Claim Form does not guarantee that you will be eligible to receive a payment from the Settlement. The distribution of the Net Settlement Fund will be governed by the Plan of Allocation set forth in the Notice, if it is approved by the Court, or by such other plan of allocation as the Court approves.
- 7. Use the Schedule of Transactions in Part II of this Claim Form to supply all required details of your transaction(s) in, and holdings of, OvaScience common stock. On this schedule, provide all of the requested information with respect to your holdings, purchases, acquisitions and sales of OvaScience common stock (including free transfers and deliveries), whether such transactions resulted in a profit or a loss. **Failure to report all transaction and holding information during the requested time period may result in the rejection of your claim.**
- 8. You are required to submit genuine and sufficient documentation for all of your transactions in and holdings of OvaScience common stock as set forth in the Schedule of Transactions in Part II of this Claim Form. Documentation may consist of copies of brokerage confirmation slips or monthly brokerage account statements, or an authorized statement from your broker containing the transactional and holding information found in a broker confirmation slip or account statement. The Parties and the Claims Administrator do not independently have information about your investments in OvaScience

common stock. IF SUCH DOCUMENTS ARE NOT IN YOUR POSSESSION, PLEASE OBTAIN COPIES OF THE DOCUMENTS OR EQUIVALENT DOCUMENTS FROM YOUR BROKER. FAILURE TO SUPPLY THIS DOCUMENTATION MAY RESULT IN THE REJECTION OF YOUR CLAIM. DO NOT SEND ORIGINAL DOCUMENTS. Please keep a copy of all documents that you send to the Claims Administrator. Also, do not highlight any portion of the Claim Form or any supporting documents.

- 9. Use Part I of this Claim Form entitled "CLAIMANT INFORMATION" to identify the beneficial owner(s) of the OvaScience common stock. The complete name(s) of the beneficial owner(s) must be entered. If you held the OvaScience common stock in your own name, you were the beneficial owner as well as the record owner. If, however, your OvaScience common stock was registered in the name of a third party, such as a nominee or brokerage firm, you were the beneficial owner of the security, but the third party was the record owner. The beneficial owner, not the record owner, must sign this Claim Form to be eligible to participate in the Settlement. If there were joint beneficial owners, each must sign this Claim Form and their names must appear as "Claimants" in Part I of this Claim Form.
- One Claim should be submitted for each separate legal entity or separately managed account. Separate Claim Forms should be submitted for each separate legal entity (e.g., an individual should not combine his or her IRA transactions with transactions made solely in the individual's name). Generally, a single Claim Form should be submitted on behalf of one legal entity, including all holdings and transactions made by that entity on one Claim Form. However, if a single person or legal entity had multiple accounts that were separately managed, separate Claims may be submitted for each such account. The Claims Administrator reserves the right to request information on all the holdings and transactions in OvaScience common stock made on behalf of a single beneficial owner.
- 11. Agents, executors, administrators, guardians, and trustees must complete and sign the Claim Form on behalf of persons represented by them, and they must:
 - (a) expressly state the capacity in which they are acting;
- (b) identify the name, account number, last four digits of the Social Security Number (or taxpayer identification number), address, and telephone number of the beneficial owner of (or other person or entity on whose behalf they are acting with respect to) the OvaScience common stock; and
- (c) furnish herewith evidence of their authority to bind to the Claim Form the person or entity on whose behalf they are acting. (Authority to complete and sign a Claim Form cannot be established by stockbrokers demonstrating only that they have discretionary authority to trade securities in another person's accounts.)
 - 12. By submitting a signed Claim Form, you will be swearing that you:
 - (a) own(ed) the OvaScience common stock you have listed in the Claim Form; or
 - (b) are expressly authorized to act on behalf of the owner thereof.
- 13. By submitting a signed Claim Form, you will be swearing to the truth of the statements contained therein and the genuineness of the documents attached thereto, subject to penalties of perjury under the laws of the United States of America. The making of false statements, or the submission of forged or fraudulent documentation, will result in the rejection of your claim and may subject you to civil liability or criminal prosecution.
- 14. If the Court approves the Settlement, payments to eligible Authorized Claimants pursuant to the Plan of Allocation (or such other plan of allocation as the Court approves) will be made after any appeals are resolved and after the completion of all claims processing. The claims process will take substantial time to complete fully and fairly. Please be patient.
- 15. **PLEASE NOTE:** As set forth in the Plan of Allocation, each Authorized Claimant shall receive his, her, or its *pro rata* share of the Net Settlement Fund. If the prorated payment to any Authorized Claimant calculates to less than \$10.00, it will not be included in the calculation and no distribution will be made to that Authorized Claimant.
- 16. If you have questions concerning the Claim Form, or need additional copies of the Claim Form or the Notice, you may contact the Claims Administrator, Gilardi & Co. LLC, at the above address, by email at info@OvaScienceSecuritiesLitigation.com, or by toll-free phone at 1-866-757-7818, or you can visit the Settlement website, www.OvaScienceSecuritiesLitigation.com, where copies of the Claim Form and Notice are available for downloading.
- 17. NOTICE REGARDING ELECTRONIC FILES: Certain Claimants with large numbers of transactions may request, or may be requested, to submit information regarding their transactions in electronic files. To obtain the *mandatory* electronic filing requirements and file layout, you may visit the Settlement website at www.OvaScienceSecuritiesLitigation.com, or you may email the Claims Administrator's electronic filing department at edata@gilardi.com. **Any file not in accordance with the required electronic filing format will be subject to rejection.** The *complete* name of the beneficial owner of the securities must be entered where called for (see Paragraph 9 above). Distribution payments must be made by check or electronic payment payable to the Authorized Claimant (beneficial account owner). The Third-Party Filer shall not be the payee of any distribution payment check or electronic distribution payment. No electronic files will be considered to have been submitted unless the Claims Administrator issues an email to that effect. **Do not assume that your file has been received until you receive this email.** If you do not receive such an email within 10 days of your submission, you should contact the electronic filing department at edata@gilardi.com to inquire about your file and confirm it was received.

Official Office

Use

Only

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

Dahhan v. OvaScience, Inc., et al.

No. 1:17-cv-10511-IT

PROOF OF CLAIM AND RELEASE

Must Be Postmarked (if Mailed) or Received (if Submitted Online) No Later Than August 22, 2022

6/21/22 Page 20 of 23

OVA

<u>Please Type or Print in the Boxes Below</u> Do <u>NOT</u> use Red Ink, Pencil, or Staples

PART I. CLAIMANT INFORMATION		
Please read "General Instructions," above, before	ons regarding this Claim For	imant Information." The Claims Administrator will m. If this information changes, you MUST notify all persons and entities must be provided.
Last Name	M.I.	First Name
Last Name (Co-Beneficial Owner)	M.I.	First Name (Co-Beneficial Owner)
IRA Joint Tenancy E	imployee Individ	dual Other
Company Name (Beneficial Owner - If Claimant	is not an Individual) or Custo	dian Name if an IRA (specify)
Trustee/Asset Manager/Nominee/Record Owner	's Name (If Different from Be	neficial Owner Listed Above)
Account#/Fund# (Not Necessary for Individual Fi	lers)	
Last Four Digits of Social Security Number	Taxpayer Identification Nu	mher
or		
Telephone Number (Primary Daytime)	Telephone Number (Alt	remate)
		_
Email Address		
MAILING INFORMATION		
Address		
Address		
City	Sta	te ZIP Code
Foreign Province	Foreign Postal Code	Foreign Country Name/Abbreviation
FOR CLAIMS PROCESSING OB CB KE	BE FL OP DR ME RE FM ND SH	MM/DD/YYYY



Capart: 11.7-sightebulle of transactions in ovaschence/commonestock23

(NASDAQ TICKER: OVAS; CUSIP 69014Q)Use this section to provide information on your holdings and trading of OvaScience common stock (NASDAQ Ticker Symbol: OVAS) ("OvaScience common stock") during the requested time periods. Please include proper documentation with your Claim Form as described in detail in the General Instructions, Paragraph 8 above.

			es of OvaSo ading on De												Proof Y	Enclo	sed? N
В. І	Purch	nases and a	-	(including	free re	ceipts) of	f OvaSci	ence commo	n stock (De	cember 1	7, 2014	– Se	ptem	ber 2	28, 201	5, incl	usive):
		Trade [Date(s) of S					of Shares I or Acquire	d	Acquis Co and Fe	otal Pu sition Pi mmissi ees). Pl neares	rice (l ons, ease	Exclı Taxe rour	uding es nd of	ff	Pur	oof of chase osed?
	М	M D	D Y	YY	Υ												
1 .		/_	/						\$							00	O Y O N
2.		/	/						\$							00	O Y O N
3.		/	/						\$							00	O Y O N
4.		/	/						\$							00	O Y O N
5.		/	/						\$							00	O Y O N
			es of OvaSc ceipts) from					r acquired ember 28, 20	15:¹						Proof Y	Enclo	sed? N
		ANIT: (i) If a			word a	"abort or		1.37									
		received sh	• •				r, please	ase mark Yes identify the oger Shares:		are amou	ınt and t		•	ny ac pany		:	
(ii) If	you M	received sh	nares throug	h an acqı Y Y	uisition o	or merge	r, please Mero	identify the	date, the sha				Com	pany		:	
(ii) If	you M	received sh D I S (including SALES -	nares throug	h an acqu Y Y ies) of Ov	uisition o	or merger	r, please Mero non stock	e identify the o	date, the sha	Decembe T (Excl T Pl		olonial in the second s	Com clusi rice nissidees).	ve):		Pro Sá	oof of ales osed?
(ii) If M	you M	received sh D I s (including SALES - Trade [(List (free deliver	h an acquired Y Y Y y ies) of Over Shares cally)	Y Y vaScience	or merger	r, please Mero non stock	ger Shares: (December of Shares	date, the sha	Decembe T (Excl T Pl	or 28, 20 Total Sa uding C axes al	olonial in the second s	Com clusi rice nissidees).	ve):		Pro Sa Encl	ales osed?
(ii) If	you M Sales	received sh D I s (including SALES - Trade [(List (free deliver	h an acquired Y Y Y y ies) of Over Shares cally)	Y Y vaScience	or merger	r, please Mero non stock	ger Shares: (December of Shares	date, the sha	Decembe T (Excl T Pl	or 28, 20 Total Sa uding C axes al	olonial in the second s	Com clusi rice nissidees).	ve):		Pro Sá	osed?
(ii) If M	you M Sales	received sh D I s (including SALES - Trade [(List (free deliver	h an acquired Y Y Y y ies) of Over Shares cally)	Y Y vaScience	or merger	r, please Mero non stock	ger Shares: (December of Shares	date, the sha	Decembe T (Excl T Pl	or 28, 20 Total Sa uding C axes al	olonial in the second s	Com clusi rice nissidees).	ve):	•	Pro Sa Encl	ales osed? Y N Y
(ii) If M D.	you M Sales	received sh D I s (including SALES - Trade [(List (free deliver	h an acquired Y Y Y y ies) of Over Shares cally)	Y Y vaScience	or merger	r, please Mero non stock	ger Shares: (December of Shares	17, 2014 – I	Decembe T (Excl T Pl	or 28, 20 Total Sa uding C axes al	olonial in the second s	Com clusi rice nissidees).	ve):		Pro Sa Encl	ales osed? Y N
(ii) If M D. 2.	you M Sales	received sh D I s (including SALES - Trade [(List (free deliver	h an acquired Y Y Y y ies) of Over Shares cally)	Y Y vaScience	or merger	r, please Mero non stock	ger Shares: (December of Shares	\$ \$	Decembe T (Excl T Pl	or 28, 20 Total Sa uding C axes al	olonial in the second s	Com clusi rice nissidees).	ve):		Pro Sa Encl	Y N Y N Y
(ii) If M D. 2. 3.	you M Sales	received sh D I s (including SALES - Trade [(List (free deliver	h an acquired Y Y Y y ies) of Over Shares cally)	Y Y vaScience	or merger	r, please Mero non stock	ger Shares: (December of Shares	\$ \$ \$	Decembe T (Excl T Pl	or 28, 20 Total Sa uding C axes al	olonial in the second s	Com clusi rice nissidees).	ve):		Pro Sa Enclo 00 00	Y N Y N Y N
(ii) If M D. 1. 2. 3. 4. 5.	M Sales	received sh D I I I I I I I I I I I I I I I I I I	pares through Y free deliver Date(s) of Schronologic D Y / des of OvaScading on Deliver	h an acquired y y y ies) of Over Shares cally) Y Y y ience correcember 2	Y yaScience Y nmon st 28, 2015	ce comm	non stock	ger Shares: (December of Shares	\$ \$ \$ \$ \$	December 1 (Excl T PI the r	or 28, 20 Total Sa uding C faxes an ease ro nearest	olonial in the second s	clusi rice eles). off to	panyve): ons, Dillar	Proof	Pro Sa Enclo	Ales osed? Y N Y N Y N Y N Y N Y N Y N Y N

YOU MUST READ AND SIGN THE RELEASE ON PAGE 6. FAILURE TO SIGN THE RELEASE MAY RESULT IN A DELAY IN PROCESSING OR THE REJECTION OF YOUR CLAIM.



PART III. RELEASE OF CLAIMS AND SIGNATURE

YOU MUST ALSO READ THE RELEASE AND CERTIFICATION BELOW AND SIGN ON PAGE 6 OF THIS CLAIM FORM.

I (We) hereby acknowledge that, pursuant to the terms set forth in the Stipulation, without further action by anyone, upon the Effective Date of the Settlement, I (we), on behalf of myself (ourselves) and my (our) (the Claimant(s)') heirs, executors, administrators, predecessors, successors, and assigns in their capacities as such, shall be deemed to have, and by operation of law and of the judgment shall have, fully, finally, and forever compromised, settled, released, resolved, relinquished, waived, and discharged any and all Released Plaintiff's Claims against Defendants and the other Defendants' Releasees, and shall forever be barred and enjoined from prosecuting any and all Released Plaintiff's Claims against any of the Defendants' Releasees, whether or not such Class Member executes and delivers the Claim Form or shares in the Net Settlement Fund.

PART IV. CERTIFICATION

By signing and submitting this Claim Form, the Claimant(s) or the person(s) who represent(s) the Claimant(s) agree(s) to the release above and certifies (certify) as follows:

- (a) that I (we) have read and understand the contents of the Notice and this Claim Form, including the releases provided for in the Settlement and the terms of the Plan of Allocation;
- (b) that the Claimant(s) is a (are) Class Member(s), as defined in the Notice, and is (are) not excluded by definition from the Class as set forth in the Notice:
- (c) that I (we) own(ed) the OvaScience common stock identified in the Claim Form and have not assigned the Claim against any of the Defendants or any of the other Defendants' Releasees to another, or that, in signing and submitting this Claim Form, I (we) have the authority to act on behalf of the owner(s) thereof;
- (d) that the Claimant(s) has (have) not submitted any other Claim covering the same purchases or acquisitions of OvaScience common stock and knows (know) of no other person having done so on the Claimant's (Claimants') behalf;
- (e) that the Claimant(s) submit(s) to the jurisdiction of the Court with respect to Claimant's (Claimants') Claim and for purposes of enforcing the releases set forth herein;
- (f) that I (we) agree to furnish such additional information with respect to this Claim Form as Lead Counsel, the Claims Administrator, or the Court may require;
- (g) that the Claimant(s) waive(s) the right to trial by jury, to the extent it exists, and agree(s) to the determination by the Court of the validity or amount of this Claim, and waives any right of appeal or review with respect to such determination;
- (h) that I (we) acknowledge that the Claimant(s) will be bound by and subject to the terms of any judgment(s) that may be entered in the Action; and
- (i) that the Claimant(s) is (are) NOT subject to backup withholding under the provisions of Section 3406(a)(1) (C) of the Internal Revenue Code because (i) the Claimant(s) is (are) exempt from backup withholding or (ii) the Claimant(s) has (have) not been notified by the IRS that he, she, or it is subject to backup withholding as a result of a failure to report all interest or dividends or (iii) the IRS has notified the Claimant(s) that he, she, or it is no longer subject to backup withholding. If the IRS has notified the Claimant(s) that he, she, it, or they is (are) subject to backup withholding, please strike out the language in the preceding sentence indicating that the Claim is not subject to backup withholding in the certification above.

Information requested with respect to your purchases and acquisitions of OvaScience common stock from September 29, 2015 through and including December 28, 2015, is needed in order to balance your claim; purchases during this period, however, are not eligible under the Settlement and will not be used for purposes of calculating your Recognized Claim under the Plan of Allocation.



Case 1:17-cv-10511-IT Document 187-1 Filed 06/21/22 Page 23 of 23

UNDER THE PENALTIES OF PERJURY, I (WE) CERTIFY THAT ALL OF THE INFORMATION PROVIDED BY ME (US) ON THIS CLAIM FORM IS TRUE, CORRECT, AND COMPLETE, AND THAT THE DOCUMENTS SUBMITTED HEREWITH ARE TRUE AND CORRECT COPIES OF WHAT THEY PURPORT TO BE.

Executed this da	y of	in
	(Month/Year)	(City/State/Country)
(Sign your name here)		(Sign your name here)
(Type or print your name here)		(Type or print your name here)
(Capacity of person(s) signing, <i>e.g.</i> Beneficial Purchaser or Acquirer, E		(Capacity of person(s) signing, e.g., Beneficial Purchaser or Acquirer, Executor or Administrator)

ACCURATE CLAIMS PROCESSING TAKES A SIGNIFICANT AMOUNT OF TIME. THANK YOU FOR YOUR PATIENCE.

Reminder Checklist:

- 1. Please sign the above release and certification.
- 2. If this Claim Form is being made on behalf of Joint Claimants, then both must sign.
- 3. Remember to attach copies of supporting documentation, if available.
- Attach only copies of acceptable supporting documentation as these documents will not be returned to you.
- 5. Keep a copy of your Claim Form and all supporting documentation for your records.
- If you desire an acknowledgment of receipt of your Claim Form, please send it Certified Mail, Return Receipt Requested.

- 7. **Do not use red pen or highlighter** on the Claim Form or supporting documentation.
- 8. If your address changes in the future, or if this Claim Form was sent to an old or incorrect address, you must send the Claims Administrator written notification of your new address. If you change your name, inform the Claims Administrator.
- 9. If you have any questions or concerns regarding your Claim, please contact the Claims Administrator at the address below, by email at info@OvaScienceSecuritiesLitigation.com, or by toll-free phone at 1 (866) 757-7818, or you may visit www.OvaScienceSecuritiesLitigation.com. DO NOT call OvaScience or its counsel with questions regarding your Claim.

THIS CLAIM FORM MUST BE SUBMITTED ONLINE USING THE SETTLEMENT WEBSITE, WWW.OVASCIENCESECURITIESLITIGATION.COM, NO LATER THAN AUGUST 22, 2022, OR MAILED TO THE CLAIMS ADMINISTRATOR BY FIRST-CLASS MAIL, POSTMARKED NO LATER THAN AUGUST 22, 2022, ADDRESSED AS FOLLOWS:

OvaScience Securities Litigation c/o Gilardi & Co. LLC P.O. Box 43312 Providence, RI 02940-3312

A Claim Form received by the Claims Administrator via mail shall be deemed to have been submitted when posted, if a postmark date on or before August 22, 2022 is indicated on the envelope and it is mailed First Class, and addressed in accordance with the above instructions. In all other cases, a Claim Form shall be deemed to have been submitted when actually received by the Claims Administrator.

You should be aware that it will take a significant amount of time to fully process all of the Claim Forms. Please be patient and notify the Claims Administrator of any change of address.





EXHIBIT B

ase $\frac{1}{4}$:17-cv-10511-IT Document 187-2 Filed 06/21/22 Page 2 of 2

1 McInnis Parkway Suite 250 San Rafael, CA 94903 P: (415) 458-3015

April 22, 2022

«FirstName» «LastName» «Company» «Addr1» «Addr2» South Bend, IN 46601 «FCountry»

Re: OvaScience Securities Litigation

Dear «GENDER» «LastName»:

Please find enclosed the Notice of (I) Proposed Settlement and Plan of Allocation; (II) Settlement Hearing; and (III) Motion for Attorneys' Fees and Litigation Expenses (the "Settlement Notice") and Proof of Claim and Release (the "Claim Form") for the above referenced litigation. Please note both the Class Period and the designated eligible securities described on page one of the Settlement Notice, specifically the inclusion of all persons or entities who purchased or otherwise acquired the publicly-traded common stock of OvaScience, Inc. ("OvaScience" or the "Company") between December 17, 2014 and September 28, 2015, inclusive (the "Class"). In addition, the Settlement Notice provides that the exclusion deadline is July 5, 2022 and the claim submission deadline is August 22, 2022.

If you previously provided the names and addresses of persons and entities on whose behalf you purchased or acquired OvaScience common stock during the period between December 17, 2014 and September 28, 2015, inclusive, in connection with the class notice (disseminated in or around July 2020) and (i) those names and addresses remain current and (ii) you have no additional names and addresses for potential Class Members to provide to the Claims Administrator, you need do nothing further at this time. The Claims Administrator will mail a copy of the Settlement Notice and the Claim Form ("Settlement Notice Packet") to the beneficial owners whose names and addresses were previously provided in connection with the Settlement Notices.

Please pay particular attention to the "What If I Bought OvaScience Stock On Someone Else's Behalf?" on page eleven of the Settlement Notice which states, in part: If you have additional name and address information, the name and address information of certain of your beneficial owners has changed, or if you need additional copies of the Settlement Notice Packet, or have not already provided information regarding persons and entities on whose behalf you purchased or acquired OvaScience common stock during the period between December 17, 2014 and September 28, 2015, inclusive, in connection with the Settlement Notice, the Court has ordered that, within seven (7) calendar days of receipt of this Settlement Notice, you must either: (i) send a list of the names and addresses of such beneficial owners to the Claims Administrator at notifications@gilardi.com or OvaScience Securities Litigation, c/o Gilardi & Co. LLC, P.O. Box 43312, Providence, RI 02940-3312, in which event the Claims Administrator shall promptly mail the Settlement Notice Packet to such beneficial owners; or (ii) request from the Claims Administrator sufficient copies of the Settlement Notice Packet to forward to all such beneficial owners, which you must then mail to the beneficial owners by First Class Mail no later than seven (7) calendar days after receipt. As stated above, if you have already provided this information in connection with the Settlement Notice, unless that information has changed (e.g., the beneficial owner has changed address), it is unnecessary to provide such information again.

Please do not make your own copies of the Claim Form, as copies may not be accepted for processing. Additional copies of the appropriate documents may be requested by contacting us at the above address and/or Notifications@Gilardi.com. If we conduct the necessary mailing on your behalf, please submit names and addresses either via email to Notifications@Gilardi.com, via CD Rom to the above address or contact us to obtain secure FTP transmission instructions. Mailing labels will be accepted, but you may be requested to provide an additional copy of the address information you send. Do not include any confidential information that should not appear on a mailing label.

Your request must also specify the case name and Control Total(s) (for example, the total number of name and address records provided) for each file submission. If you have any questions, please email Motifications@Gilardi.com.

Sincerely, Gilardi and Company, LLC

EXHIBIT C

NEW HIGHS AND LOWS

WSJ.com/newhighs

Continued Fr	om Dago PO	1	5	2-Wk %	ı		52-Wk %	ı	5	2-Wk %	1		52-Wk %	ı		52-Wk %	ĺ		52-Wk %	1	52	-Wk %	1	52-Wk %	1	52-1	Wk %
Continued Fi	52-Wk %	Stock		Hi/Lo Chg	Stock		Hi/Lo Chg	Stock		Hi/Lo Cho	Stock		Hi/Lo Chg	Stock		Hi/Lo Chg	Stock		Hi/Lo Cho	Stock		i/Lo Chg	Stock Syr	n Hi/Lo Cho	Stock	Sym Hi/	
Stock	Sym Hi/Lo Ch	ArborRltvPfdF	ADD-F	22.20 1.5	Danita - Diankara	- DNTC	1.2/ 0.0				1									1							
			ACLX		BenitecBiopharn BicycleTherap	BCYC	1.26 -9.0 21.20 -5.6	canavia, con		20.43 -4.8			5.04	EdibleGarden	EDBL	2.46 -42.2	FirstHorizonPfo					22.15 -1.7	InnovativeIndProp IIPF				0.04 -22.0
AethlonMedica		4 Arcellx			Big5SportingGd		14.01 -2.2	Camarasinicia		13.70 -4.4	Confluent	CFLT	27.43 -15.5	EdifyAcqnWt	EACPW	0.13 -3.0	FirstRepBkPfo					0.92 -1.7	InnovativeIntIWt IOA		LancasterColony		
AffiliatedNts61		7 ArgusCapitalM		0.20 -2.3		BIG	30.45 -4.2	Calyxt	CLXT	0.37 -8.2			0.68 -14.7	EducDev	EDUC	4.38 -22.9	FirstRepBkPfo					23.20 -0.9			LatchWt).45 -11.3
AffiliatedMgrDe		A			BioAtla	BCAB	2.33 -41.2	Cannae		21.70 -5.2		CSTM	15.34 -6.7	EffectorTherap		2.80 -4.3				GreenwichLife		10.84 -8.4			LeapTherap		1.19 -8.2
AffiliatedNts60		1 ArrowrootAcanV			BioLifeSols	BLFS	12.03 -6.7	CanooWt	GOEVW	0.79 -13.2		C00	344.03 -4.0	ElancoAnimal	ELAN	23.97 -3.3	FirstRepBkPfd				GRTS	2.53 -5.8	InsightAcqnWt INAQ		LegatoMergerIIWt).29 -9.4
Agenus	AGEN 1.71 -7	Arteris	AIP		BioPlusAcqnW			Canoo CapitolFedFin	GOEV CFFN		CooTekCayma CostamarePfd		0.12 -5.0	ElancoAnimalU	n ELAT ESTC	38.13 -3.1 66.14 -9.7	FirsthandTech\	FSV	3.00 0.3 118.89 -3.3		GNACW	0.71 -1.1	InspiraTech IINI InspiraTechWt IINI		LendingTree		1.27 5.0 2.60 -10.9
AirspanNetworksV		Arvinas		47.27 -9.9		BVS	9.15 -4.9	Capitoiredrin	CPRI	9.44 -2.0 44.34 -7.3		CPNG	25.52 -0.6 11.91 -10.3	Elastic	ECOR	0.40 -2.5	FirstService FlexShopper	FPAY	1.00 -2.9		AVAL	3.93 -1.7					5.81 -3.5
Akerna	KERN 0.64 -3	Acana		25.81 -11.3		BRDS	1.54 -11.4	CaraTherap	CARA	8.23 -4.0		CXDO		electroCore		1.44 -3.2		FOR	15.59 -4.7			8.54 -5.8	Inspirato ISP InstilBio TIL		LibertyLatAmA		3.60 -8.9
AlamoGroup	ALG 121.29 -6	A	ASXC	0.39 -10.4		NILE	0.35 -8.9	Cara merap	LOTZW	0.13 -13.3			2.50 0.8 1.02 -9.3	ElysGameTech Emcore	EMKR	3.05 -14.7	Forestar FormaTherap						Instilbio III. IntegraLifeSci IAR		LibertyLatAmC		3.57 -8.8
Alector	ALEC 9.18 -6	AslanDharm	ASLN		BlackDiamond		2.21 -5.9	CarLotz	LOTZ	0.84 -8.6				EmpowerIWt	EPWR.WS	0.08 8.8	FortistarSustV				HEVO		Integral/Acon1Wt INT				1.58 -6.7
AlerisLife	ALR 1.50 -6	A -+ A \ A //			BlackMountainW		0.15 -25.9	Cars.com	CARS		Curis	CDIC	0.17 -10.0	Endeavor	EDR	18.81 -8.4	FortressTranspo		18.51 0.7		HIGA.WS	0.24 -11.1	Integral Acquit VV INT				3.11 -5.5
AligosTherap	ALGS 1.07 -11	ALL DOID	ATHpB	21.66 -1.8	Blackbaud	BLKB	52.22 -6.6	Carter's	CRI		CycloTherap	CYTH	2.27 -9.8		EFOI	1.00 -7.2			10.67 -8.7			0.76 -8.1	ICE ICE		LigTechIntl		1.26 -3.8
AlkalineWater AlkamiTech	WTER 0.55 -24 ALKT 11.57 -9	0	ATHpD	19.00 -3.6		BL	61.73 -8.6		CVNA	47.45 -18.0			1.99 -9.0		ENJYW	0.11 5.1	FrazierLifesW			HUTCHMED(China			IntlMediaAcgnWt IMA		LiquiditySycs		1.03 -2.3
	ALKI 11.57 -9 ALLK 3.48 -6	AtlanticusNts2			BlinkCharging	BLNK	17.91 -7.6	CastleBiosci		21.48 -9.8	-,	CYT	1.94 -18.0	EnlivexTherap	ENLV	3.65 -8.9	Freedoml Wt				HGTY	8.54 -2.2			LivaNova		1.54 -12.3
Allakos AllarityTherap		O A. TI			BlockchainMoonR		0.12 -42.7	Cazoo	CZOO	1.06 -18.0			1.56 -5.8			23.80 -0.9	FrequencyElec		7.67 -2.8				InvescoMta IVR		LiveRamp		3.29 -7.0
AllenaPharm	ALIK 1.42 -1 ALNA 0.10 -24		ATRC		BoltBiotherap	BOLT	1.47 -7.5	Centogene	CNTG	3.12 2.9	DIRTT Envl	DRTT	0.92 -7.8	EpiphanyTechW		0.21 -14.5	FreshDelMont		23.42 -2.7				InvestcorpEur I Wt IVCI		loanDepot		2.74 -4.7
AlliedEsports	AESE 1.42 -7	AuburnNatlBno			Braskem	BAK	15.73 -5.7	CentralGarden		42.24 -0.5			18.64 -3.4		FDDT	22.69 -3.2	Freshpet	FRPT	68.06 -14.5			12.70 -10.4			LogicMark		1.56 -14.6
AllstatePfdl	ALLpl 20.02 -3	8 AudioEye	AEYE		BridgelineDigita		1.31 -8.1	CntlValCmntvE			DAVIDSTEA	DTEA	2.17 -4.3	Etsv	ETSY	88.88 -16.8	FrontierInvtW					0.23 -6.0			LogitechIntl		2.25 -4.1
AlphaPtrsWt	APTMW 0.15 17		AUST		BrightHorizons		91.66 -8.7	CenturyTherap		10.46 -14.0			0.16 8.4	EvofemBiosci	EVFM	0.11 -32.9	FultonFinlPfd					6.25 -2.9			LoyaltyVentures		0.95 -6.5
AlphaStarRt	ALSAR 0.14 -0	6 Avalara	AVLR	69.14 -13.0	BrightMindsBig	DRUG	0.85 1.6	CeridianHCM	CDAY	54.76 -7.8		DLX	25.75 -6.7	ExelaTechPfdB		6.75 -10.0	FusionAcgnIIV					24.99 -1.2			LuminarTech		1.12 -9.0
AlphaTeknova	TKNO 10.02 -2	6 AvaloTherap	AVTX	0.31 -16.3	BrighthousePfdl	B BHFAO	24.70 -0.9			13.47 -6.2	DenaliTherap	DNLI	23.39 -10.3	ExelaTech	XELA	0.31 -5.9	FuweiFilms	FFHL	5.23 -10.0			4.10 -11.0	IterumTherap ITR				5.31 -5.1
AltairEngg	ALTR 52.62 -4	1 AveannaHealtl	h AVAH	2.73 -6.4	BrighthouseFinIPf	C BHFAN	19.68 -3.9	SchwabPfdD		24.76 -1.0		DENN	10.50 -4.7	Expedia	EXPE	135.00 -6.7		GHRS	11.79 -12.7			0.40 -6.2				MFApB 23	
AltimarIIIWt	ATAO.WS 0.33 1	0 AvidBioservice	s CDMO	12.66 -9.4	BrightSpire	BRSP	7.97 -4.7	ChathamLodgPt			DiamondHeadV		0.21 14.5	Exscientia	EXAL	9.24 -11.3		GMVD				15.22 -7.7	J&JSnackFoods JJS			MSCI 405	
Altimmune		AxonEnterpris		96.32 -13.9	Brink's	BCO	55.81 -5.7	Check-Cap Wt	C CHEKZ	0.06 32.3			3.92 -7.0	Evenovia	EYEN			a GTBP	1.71 -9.9	HlthcrSvcsWt			JBG SMITH Prop JBG		MacondrayCapIWt	DRAYW 0	0.15 6.8
AlumofChina		6 AxosFinancial		36.79 -5.5	Broadstone	BNL	19.53 -3.8	ChemomabThera	D CMMB	2.90 -3.1	DigitalBrands	DBGI	0.48 -8.0	FastAconII Wt	FZT.WS	0.25 -9.8					HLBZ	1.32 -4.9	JawsJuggernautWt JUG		Macrogenics	MGNX 5	5.03 -19.6
Amarin		5 AyalaPharm	AYLA	2.38 -3.3	BrookfieldBRP Nt	s BEPH	16.90 -0.9	CherryHillPfdB	CHMIpB	22.75 -1.5	DigitalHlthWt	DHACW	0.09 -0.7	F45Training	FXLV	7.77 -9.7	GabelliDivPfdl	K GDVpK	18.39 -0.9	HennessyCapInvVIV		0.46 -6.1	JerashHldgs JRS	H 5.32 -10.	MaidenPfdC	MHpC 5	5.99 -9.1
Amazon.com	AMZN 2301.45 -7	6 BarkWt	BARK.WS	0.42 -6.6	BrookfldBRP4.875N	t BEPI	17.75 -2.9	ChromaDex	CDXC	1.81 -7.1	DigitalOcean	DOCN	34.25 -18.1	FS Bancorp	FSBW	28.81 -2.5	GabelliEqPfdG	GABpG	22.81 -2.0	HeronTherap	HRTX	4.28 -9.4	JohnsonOutdoors JOU	T 75.00 -4.1	MalaccaStraitsWt	MLACW 0	0.06 -35.0
Ambarella	AMBA 77.46 -9	3 BIPBermudaNt	ts BIPI		BrookfieldBus	BBUC	22.72 -6.9	Cimpress	CMPR	48.27 -11.9	dLocal	DLO	21.85 -10.0	FstarTherap	FSTX	2.43 -7.1	GencorIndustri	ies GENC	9.66 -2.0) Heska	HSKA 1	01.64 -6.9	Joint JYN	T 27.17 -7.	MarinusPharma	MRNS 5	5.76 -1.1
Amedisys		9 BitMining	BTCM	1.52 -11.5	BrookfieldBusPt	r BBU	21.70 -3.0	CircorIntl	CIR	18.23 -7.3	dMYTechGrpVIV	Vt DMYS.WS	0.50 -12.1	FTACZeusAcqnV	t ZINGW	0.23 -6.9	GeneticTechs	GENE	1.50 -4.3	HighTide	HITI	3.22 -7.7	JounceTherap JNC	E 4.79 -6.9	Maris-TechWt	MTEKW 0).22 15.3
AmOutdoorBrand	is AOUT 12.22 -3	9 BM Tech	BMTX	6.93 -2.7	BrookfieldFinNt	s BAMI	18.00 -1.5	CitigroupPfdK	CpK	25.53 -0.9	Doma	DOMA	1.65 -7.2	FarPeakAcqnW	t FPAC.WS	0.68 -6.8	GenoceaBiosc	i GNCA	0.24 -5.7	HighwayHldgs	HIHO	2.25 -0.1	JourneyMed DEF	M 3.57 -6.4	MarketWise	MKTW 3	3.52 -3.2
AmerSoftware		1 BM Tech Wt	BMTX.WS		BrookfieldFinNt		17.87 -2.2	Citizens	CIA	2.50 -9.0	DomaWt	DOMA.WS	0.13 -5.9	FaradayFutureV	t FFIEW	0.25 -7.5	Genpact	G	37.68 -5.6	Honest	HNST	3.83 -10.5	JPMorganPfdDD JPN	pD 23.75 -1.4	MarkforgedWt).42 -9.4
AmVirtualClou	d AVCT 0.57 -9	0 BRF	BRFS	2.39 -8.5	Brooklynlmmun	o BTX	0.94 -6.7	ClassAccelWt	CLAS.WS	0.14 -9.8	DoorDash	DASH	70.04 -10.4	Farfetch	FTCH	9.80 -10.4	GeoVaxLabsV	Vt GOVXW	0.35 -4.7	7 HookerFurnishing	gs HOFT	16.71 -2.1	KinsTechWt KIN	ZW 0.05 0.1	Marygold	MGLD 1	L.21
Ametek		9 B.RileyNts202			BurfordCapital		8.11 -3.7	ClearOne	CLRO	0.60 4.2			5.71 -5.2	FateTherap	FATE	26.82 -11.4	GigCapital5W				HZN	3.44 -0.8			Matterport		5.23 -6.0
AmicusTherap		7 B.RileyPrin250V	/t BRIVW		ButterflyNtwk		3.07 -6.4	ClimateRock	CLRCU		DukeEnerDeb7		24.78 -1.2	FedAgricPfdG	AGMpG	19.31 -1.7	Gildan	GIL	31.32 -11.0				KoreGroup KOF		Maximus		5.78 -7.3
Amplitech	AMPG 2.43 -5	4 Babylon	BBLN		CF Acqn IV W		0.25 -12.8	CodereOnlineV		0.30 -14.4			15.18 -4.5	FedAgricMtgPfd		25.50 -3.6	GinkgoBioworks\) HudsonPacificPfd					Mediaco		2.31 1.2
AnaptysBio	ANAB 20.56 -11		BLL		CFAcqnVII Wt		0.25 -1.3	Cognex		59.73 -10.4		DYAI	1.74 -12.6	Ferguson		119.91 -4.6						0.17 -12.8			MeiraGTx		0.61 -7.1
Anghami		9 BankofAmPfd2				CIXX	12.67 -4.4	Cohbar	CWBR	0.20 -10.3		DT	36.44 -10.3	FibroGen	FGEN	8.68 -8.3						8.16 -10.3			MelcoResorts		.12 -8.6
AngioDynamic		5 BankofAmPfdl			CMSEnerDeb78		23.82 -2.5	ColumbiaSportsv		78.93 -4.4	E-HomeHouseho		0.49 -8.7	FidelityD&D	FDBC	36.39 -4.6			21.17 -8.9	,			KatapultWt KPL		MetaFinancial		L.74 -4.4
AnikaTherap	ANIK 20.25 -7	BankofAmPfdl			CMSEngyPfdC		17.55 -2.4	CommVaultSy		58.66 -5.3			0.12 -5.7	FieldTripHealth		0.92 -3.1	Globant		199.93 -5.0			77.43 -6.4			MetenHolding).09 -15.2
Apartmtlnv		1 BankHawaiiPfd			CN Energy	CNEY	1.32 -4.9	CompassDigitalV		0.28 -34.0			0.20 -20.0	FiestaRestaurar		6.22 -5.7	GloryStarNewMe									METpA 22	
APi Group		2 BankFinancial			CompassPath	CMPS	8.75 -7.7	CompassPfd		25.12 -0.8			0.26 -14.9	FifthThirdPfdB		24.56 -3.1	GlycoMimetic		0.67 -9.6		IDEX		KingswoodWt KWA		MicroStrategy	MSTR 305	
AppliedGenetic		0 BannerAcqn	BNNRU		Curo	CURO	9.04 -7.3	CompassDivers		20.37 -3.0			19.32 -2.8	FinServ II Wt	FSRXW	0.23 -25.6	GoldRoyaltyW						KintaraTherap KTF				0.60 -0.3
Applovin		5 Barnes&NobleEdu			CableOne	CABO 3		ComputeHlthW		0.36 -10.2			25.05 0.2	FirstCapital	FCAP	33.55 -5.0					IMUX		KioraPharm KPF		MidwestHolding		1.00 -1.8
ApreaTherap		2 BauschHealth			CadenceBkPfd/			comScore	SCOR	1.90 -6.3		EAR	2.49 -16.7	FirstCitizenPfd								19.22 -3.0			MillerIndustries		5.22 -2.5
APxAcqnI Wt		 BayFirstFinanci 			Caesarstone	CSTE	9.09 -6.6	ComtechTel	CMTL		EastRscsAcqnV		0.14 3.4	FirstCitizensPfd			GoodRx	GDRX				14.71 -4.9			Mind CTI		2.52 -1.0
ApyxMedical		6 BeamTherap	BEAM		CalavoGrowers		31.60 -7.1			0.37 -15.5		EML	22.50 -3.0				GoresIX Wt	GHIXW			INFN	6.31 -6.1					2.04 -7.6
Aravive	ARAV 1.29 -7	5 BenessereCapV	At BENEM	0.35 -17.0	CarWtrSvc	CWT	50.00 -2.3	ConcordAcqnIIIV	VT CNDB.WS	0.29 -11.7	eBay	EBAY	47.29 -11.7	FirstHorizonPfd	C FHNpC	25.49 0.1	Graco	GGG	61.44 -4.2	2 InflectionPointU	in IPAXU	9.78 -0.9	LXP Industrial LXP	11.75 -5.4	Contin	ued on Pa	age B11

ADVERTISEMENT

The Marketplace

To advertise: 800-366-3975 or WSJ.com/classifieds

BIDS & PROPOSALS

This announcement is neither an offer to purchase nor a solicitation of an offer to sell the common shares of Imperial Oil Limited. The Offer (as defined below) is made solely by the Offer to Purchase, dated May 6, 2022, and the accompanying Issuer Bid Circular, and the related Letter of Transmittal, and Notice of Guaranteed Delivery and any amendments or supplements thereto. The Offer is not being made to, nor will tenders be accepted from or on behalf of, holders of the Shares (as defined below) in any jurisdiction in which the making or acceptance of offers to sell the Shares would not be in compliance with the laws of that jurisdiction. In any jurisdiction where the securities, blue sky, or other laws require the Offer to be made by a licensed broker or dealer, the Offer shall be deemed made on behalf of Imperial Oil Limited by the Dealer Manager (as defined below) or one or more brokers or dealers registered under the laws of such jurisdiction.

Imperial Imperial Oil Limited of

Up to C\$2,500,000,000 in Value of its Common Shares At a Purchase Price of Not Less Than C\$62.00 per Common Share And Not More Than C\$78.00 per Common Share

And Not More Than C578.00 per Common Share

Imperial Oil Limited, a Canadian corporation (the "Company"), is offering to purchase for cancellation a number of the Company's common shares (each, a "Share"), having an aggregate purchase price not exceeding C52,500,000,000 pursuant to: (i) auction tenders in which the tendering shareholders specify the number of Shares being tendered at a specified price (the "Auction Price") of not less than C562.00 and not more than C578.00 per Share in increments of C50.25 per Share (the "Auction Tenders"), (ii) purchase price tenders, in which the tendering shareholders she on to specify a price per Share, but rather agree to have a specified number of Shares purchased at the Purchase Price tenders, or or this proportionate tenders, in which the tendering shareholders do not specify a price per Share, but rather agree to have a number of Shares purchased at the Purchase Price to be determined pursuant to the Offer to Purchase (as defined below) to be determined pursuant to the Offer to Purchase that will result in them maintaining their respective proportionate Eshares ownership (the "Proportionate Tenders), upon the terms and subject to the conditions described in the Offer to Purchase, dated May 6, 2022 (the "Offer to Purchase"), and the accompanying Issuer Bid Circular (the "Issuer Bid Circular") and the related Letter of Transmittal (the "Letter of Transmittal") and notice of guaranteed delivery (the "Notice of Guaranteed Delivery") (which together, as they may be amended and supplemented from time to time, constitute the "Offer").

THE OFFER WILL EXPIRE AT 5:00 P.M., CALGARY TIME, ON JUNE 10, 2022, OR AT SUCH LATER TIME AND DATE TO WHICH THE OFFER MAY BE EXTENDED BY THE COMPANY (THE "EXPIRATION DATE"), UNILESS WITHDRAWN.

The Offer is not conditional upon any minimum number of Shares being properly deposited under the Offer. The Offer is, however, subject to other conditions as set forth in the Offer to Purchase.

Offer to Purchase.

Upon the terms and subject to the conditions of the Offer, the Company will determine a single price per Share (the "Purchase Price"), not less than C\$62.00 and not more than C\$78.00 per Share (in increments of C\$0.25 per Share), that the Company will pay for Shares properly tendered to and not properly withdrawn from the Offer, taking into account the Auction Prices and the number of Shares deposited pursuant to Auction Tenders and Purchase Price Tenders. The Purchase Price will be the lowest price that enables the Company to purchase that number of Shares pursuant to Auction Tenders and Purchase Price Tenders. The Purchase Price will be the lowest price that enables the Company to purchase that number of Shares pursuant to Audion Tenders and Purchase Price Tenders. The Purchase Price will be the lowest price that enables the "Auction Tender Limit Amount") equal to (i) C\$2.500,000,000 less (ii) the product of (A) C\$2.500,000,000 and (8) a fraction, the numerator of which is the aggregate number of Shares owned by shareholders making valid Proportionate Tenders, and the denominator of which is the aggregate number of Shares outstanding at the time of the Expiration Date. All Shares the Company purchases in the Offer will be acquired at the same purchase price regardless of whether any shareholder tenders at a lower price. Only Shares properly tendered at prices at or below the Purchase Price and Purchase Price Tenders of "Odd lot" priority and proration described in the Offer vibre of Company purchases and purchase and the Offer vibre of the Auction Tenders and Purchase Price and Purchase Price Tenders (the "Auction Tender Purchase Amount") is greater than the Auction Tender Limit Amount. Shares not purchased in the Offer will be recredited or returned to the depositing shareholders at the Company could purchase August the Expiration Date of the Offer. The Company reserves the right, in its sole discretion, to change the purchase price and purchase price of C\$62.00 per Share, the Company cou

or purchase prices to render their shares.

The Company expressly reserves the right, in its sole discretion, at any time and from time to time, to extend the period of time during which the Offer is open or to vary the terms and conditions of the Offer by giving written notice, or oral notice to be confirmed in writing, of extension or variation to Computershare Investor Services, Inc., the depositary for the Offer (the "Depositary"), and by causing the Depositary to provide to all shareholders, where required by law, as soon as practicable thererafter, a copy of the notice in the manner set forth in the Offer to Purchase. Promptly after giving notice of an extension or variation to the Depositary, but, in the case of an extension, no later than 9:00 A.M., Calgary time, on the next Business Day (defined herein as any day other than a Saturday, a Sunday, a statutory holiday in Calgary, Alberta or Toronto, Ontario and a United States federal holiday) following the last previously scheduled or announced Expiration Date, the Company will make a public announcement of the extension or variation and provide or cause to be provided notice of such extension or variation to the TSX, NYSE American and the applicable Canadian securities regulatory authorities.

The Offer will expire at 5:00 PM. Calgary time, on June 10:202 unless the Company experises its right, in its sole discretion, to extend the period of time during which the

cause to be provided notice of such extension or variation to the TSX, NYSE American and the applicable Canadian securities regulatory authorities.

The Offer will expire at 5:00 P.M., Calgary time, on June 10, 2022, unless the Company exercises its right, in its sole discretion, to extend the period of time during which the Offer will remain open. Beneficial owners should be aware that their broker, dealer, commercial bank, trust company or other nominee may establish its own earlier deadlines for participation in the Offer. Accordingly, beneficial owners wishing to participate in the Offer in order to participate in the Offer.

In accordance with the instructions to the Letter of Transmittal, shareholders wishing to tender Shares must indicate whether he or she tenders Shares pursuant to an Auction Tender, a Purchase Price Tender or a Proportionate Tender. If electing to tender his or her Shares sursuant to an Auction Tender, the tendering shareholder must specify the number of Shares that it wishes to sell and the price, not greater than CS78.00 nor less than CS6.200 per Share, shith he or she is willing to sell his or her Shares to the Company in the Offer. All Shares tendered by a shareholder who fails to specify any Auction Tender price for its Shares, or fails to indicate that he or she has tendered its shares pursuant to a Purchase Price Tender or a Proportionate Tender, will be considered to have been tendered pursuant to a Purchase Price Tender. Shareholders who makes an invalid Proportionate Tender, including by tendering an insufficient number of Shares, will be deemed to have made a Purchase Price Tender. Shareholders wishing to tender Shares must follow the procedures set forth in the Offer to Purchase, Issuer Bid Circular and in the related Letter of Transmittal (and, if applicable, the Notice of Guaranteed Delivery).

The Purchase Price will be payable in Canadian dollars; however, shareholders may elect to receive the Purchase Price in United States dollars as described in the Offer. The risk of any fluctuation in exchange rates, including risks relating to the particular date and time at which funds are converted, will be borne solely by the shareholder wishing to receive payment in United States dollars.

If the Auction Tender Purchase Amount is less than or equal to the Auction Tender Limit Amount, the Company will purchase at the Purchase Price all Shares so tendered pursuant to Auction Tender at or below the Purchase Price and Purchase Price Tenders. If the Auction Tender Purchase Amount is greater than the Auction Tender Limit Amount, the Company will purchase a portion of the Shares so tendered pursuant to Auction Tenders at or below the Purchase Price Tenders, as follows: first, the Company will purchase all Shares tendered at or below the Purchase Price by shareholders who own fewer than 100 Shares (the "Odd Lot Holders") at the Purchase Price; and

the Purchase Price; and second, the Company will purchase at the Purchase Price on a pro rata basis that portion of the Shares tendered pursuant to Auction Tenders at or below the Purchase Price and Purchase Price Tenders having an aggregate purchase price, based on the Purchase Price, equal to (A) the Auction Tender Limit Amount, less (B) the aggregate amount paid by the Company for Shares tendered by Odd Lot Holders. Regardless of proration, the Company will always purchase at the Purchase Price, payable in cash (subject to applicable withholding taxes, if any), a number of Shares from shorlodders making valid Proportionable Tenders that results in such tendering shareholders maintaining their respective proportionate Share ownership in the Company following completion of the Offer (subject to nominal differences due to the quantity of Shares purchased from such shareholders being rounded down to the nearest whole number of Shares to avoid the nurchase of fractional Shares? purchase of fractional Shares).

Payment for Shares accepted for payment pursuant to the Offer will be made only after timely receipt by the Depositary of (i) the share certificates for all Shares proposed to be taken up in proper form for transfer, together with a properly completed and duly executed Letter of Transmittal (or a manually executed photocopy thereof) or, in the case of a book-entry transfer, a Book-Entry Confirmation or an Agent's Miessage (each as defined in the Offer to Purchase), as applicable, in lieu thereof relating to such Shares, with signatures that are guaranteed if so required in accordance with the Letter of Transmittal, and (ii) any other documents required by the Letter of Transmittal. In the event of proration of Shares deposited pursuant to the Auction Tenders and Purchase Price Tenders, the Company will determine the proration factor and pay for those deposited Shares accepted for payment as soon as practicable after the Expiration Date. However, the Company does not expect to be able to announce the final results of any such proration until approximately three (3) Business Days after the Expiration Date.

production that approximately office (3) business Days after the Explantion Date.

Deposits of Shares are irrevocable, except that Shares may be withdrawn by the shareholder (a) at any time if the Shares have not been taken up by the Company before actual receipt by the Depositary of a notice of withdrawal in respect of such Shares, (b) at any time before the expiration of ten (10) days from the date that a notice of change or variation (mills expiration, (ii) the variation consists solely of an increase in the consideration offered for those Shares pursuant to the Offer where the time for deposit is not extended for greater than ten (10) days, or (iii) the variation consists solely of an increase of the walver of a condition of the Offer) has been given in accordance with the terms of the Offer to Purchase; or (c) at any time if the Shares have been taken up but not paid for by the Company within three (3) Business Days of being taken up.

or the waver or a condition of the Orier has been given in accordance with the terms of the Orier to Purchase; or (c) at any time if the shares have been taken up but not paid for by the Company within three (3) Business Days of being taken up.

For a withdrawal to be effective, a written or printed copy of a notice of withdrawal must be actually received by the Depositary by the applicable date specified above at the place of deposit of the relevant Shares. Any such notice of withdrawal must be signed by or on behalf of the person who signed the Letter of Transmittal or Notice of Guaranteed Delivery in respect of the Shares being withdrawan in the same manner as the participant's name is listed on the applicable Book-Entry transfer described in the Offer to Purchase, any notice of withdrawan bust be signed by such participant in the same manner as the participant's name is listed on the applicable Book-Entry Confirmation or on the applicable Agent's Message, and must specify the name of the person who deposited such shares, and the number of shares to be withdrawn, the name of the registered holder, if different from that of the person who deposited such shares, and the number of shares to be withdrawn, the name of the registered holder, if different from that of the person who deposited such shares, and the number of shares to be withdrawn, the name of the registered holder, if different from that of the person who deposited such shares, and the number of shares to be withdrawn, the name of the registered holder, if different from that of the person who deposited such shares, and the number of shares to be withdrawn, the name of the registered holder, if different from that of the person who deposited such shares and the shares to be withdrawal must be guaranteed by an Eligible Institution (as defined in the Offer to Purchase), except in the case of shares depositing shares depositing the shares in the course of a viderices to a share share in the course of a viderices of the person shall be obligated to give

Arison's overenimen in the rection's appropriate in their particular intensions are the propriate in the particular intensions are the particular intensions and a transfer at a table dividend on a separate class of shares comprising the Shares so sold equal to the excess of the amount paid by the Company for the Shares, being the Purchase Price, over their paid-up capital for purposes of the Tax Act. The Company estimates that on the Expiration Date the paid-up capital per Share should not exceed \$1.75 for purposes of the Tax Act. As a result, the Company expects that a Resident Shareholder who disposes of Shares under the Offer will be deemed to receive a taxable dividend. The exact quantum of the deemed dividend cannot be guaranteed.

or Shares under the Utre Will be deemed to receive a taxable dividend. The exact quantum or the deemed outleden Cannot be guaranteed.

A Non-Resident Shareholder (as defined in the Offer to Purchase) who disposes of Shares pursuant to the Offer will be deemed to receive a dividend equal to the excess of the amount paid by the Company for the Shares, being the Purchase Price, over their paid-up capital for Canadian income tax purposes. As a result, the Company expects that Non-Resident Shareholders who dispose of Shares under the Offer will be deemed to receive a dividend. The Company estimates that on the Expiration Date the paid-up capital per Share should not exceed \$1.75 for purposes of the Tax Act. The exact quantum of the deemed dividend cannot be guaranteed. Any such dividend will be subject to Canadian withholding tax at a rate of 25% or such lower rate as may be provided under the terms of an applicable Canadian tax treaty.

Generally, the purchase of shares from a shareholder that is a U.S. Holder (as defined in the Issuer Bid Circular) will be a taxable transaction for U.S. federal income tax purposes. As a consequence of any such purchase, a U.S. Holder will, depending on the U.S. Holder's particular circumstances, be treated either as having sold its Shares or as having received a distribution in respect of such Shares.

All shareholders should read carefully the Offer to Purchase and the accompanying Issuer Bid Circular for additional information regarding the income tax consequences of participating in the Offer and should consult their financial and tax advisors.

participating in the Offer and should consult their financial and tax advisors.

The Board of Directors has approved the Offer. However, none of the Company, the Special Committee (as defined in the Offer to Purchase) or the Board of Directors, the Dealer Manager or the Depositary makes any recommendation to any shareholder as to whether to deposit or refrain from depositing Shares under the Offer. Shareholders are urged to evaluate carefully all information in the Offer, consult their own financial, legal, investment and tax advisors and make their own decisions as to whether to deposit Shares under the Offer, own any Shares to deposit and the other to specify a price and, if so, at what price to deposit such Shares. No director or officer of the Company has advised the Company that he or she intends to deposit Shares under the Offer. The information required to be disclosed by Rule 13e-4(d)(1) of the Securities Exchange Act of 1934, as amended, is contained in the Offer to Purchase and is incorporated herein by reference. The Company is also filing with the Securities and Exchange Commission an Issuer Tender Offer Statement on Schedule TO, which includes certain additional information

Copies of the Offer to Purchase, accompanying Issuer Bid Circular and the related Letter of Transmittal and Notice of Guaranteed Delivery are being mailed to all holders of the Shares, including brokers, dealers, commercial banks and trust companies whose names, or the names of whose nominees, appear on the Company's shareholder list or, if applicable, who are listed as participants in a clearing agency's security position listing for subsequent transmittal to beneficial owners of Shares. The Offer is explained in detail in those

Questions or requests for assistance may be directed to the Depositary or the Dealer Manager, at their respective addresses, telephone numbers and emails, as applicable and as set forth below. Copies of the Offer to Purchase, accompanying Issuer Bid Circular, the Letter of Transmittal, the Notice of Guaranteed Delivery and other related materials will be furnished promptly by the Depositary at the Company's expense. Shareholders may also contact their broker, dealer, commercial bank, trust company or other nominee or trust company for assistance concerning the Offer.

The Depositary for the Offer is: Computershare Investor Services Inc. Regular Mail Computershare Investor Services Inc. P.O. Box 7023 31 Adelaide Street East Toronto, ON M5C 3H2 Attention: Corporate Actions By Registered Mail or Hand Carrier 100 University Avenue 8th Floor Toronto, ON M5J 2Y1 Attention: Corporate Action Telephone (outside North America): 1 (514) 982-7555 Toll-Free (within North America): 1 (800) 564-6253 Email: corporateactions@computershare.com The Dealer Manager for the Offer is: RBC Capital Markets Royal Bank Plaza, South Tower 200 Bay Street, 4th Floor Toronto, ON M5J2W7 Email: ImperialSIB@rbccm.com

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

FADI DAHHAN, Individually and on Behalf of All Others Similarly Situated, CLASS ACTION

Plaintiff.

OVASCIENCE, INC., et al.,

Defendants

SUMMARY NOTICE OF (I) PROPOSED SETTLEMENT AND PLAN OF ALLOCATION; (II) SETTLEMENT HEARING; AND (III) MOTION FOR ATTORNEYS' FEES AND LITIGATION

All persons or entities who purchased or acquired OvaScience, Inc. ("OvaScience") common stock between December 17, 2014 and September 28, 2015, inclusive (the "Class") 1

PLEASE READ THIS NOTICE CAREFULLY; YOUR RIGHTS WILL BE AFFECTED BY THE SETTLEMENT OF A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Massachusetts (the "Court"), that Lead Plaintiff and Class Representative Freedman Family Investments LLC, on behalf of itself and the Court-certified Class in the above-captioned securities class action (the "Action"), has reached a proposed settlement of the Action with defendants OvaScience, Michelle Dipp, Jeffrey E. Young, Longwood Fund, L.P., Longwood Fund, GP, LLC, and Richard Aldrich (collectively, "Defendants") for \$15,000,000 in cash that, if approved, will resolve all claims in the Action.

A hearing will be held on **July 26**, **2022**, **at 2:45 p.m.**, before the Honorable Indira Talwani either in person at the United States District Court for the District of Massachusetts, John Joseph Moakley U.S. Courthouse, I Courthouse Way, Boston, MA 02210, or by telephone or video conference (at the discretion of the Court) to, among other things: way, Boston, MA 02210, or by telephone of video conference (at the discretion of the Court) to, among other things: (i) determine whether the proposed Settlement on the terms and conditions provided for in the Stipulation and Agreement of Settlement dated March 4, 2022 (the "Stipulation") is fair, reasonable, and adequate to the Class, and should be finally approved by the Court; (ii) determine whether the Action should be dismissed with prejudice against Defendants, and the Releases specified and described in the Stipulation and the Settlement Notice should be granted; (iii) determine whether the proposed Plan of Allocation should be approved as fair and reasonable; (iv) determine whether Lead Counsel's motion for attorneys' fees and Litigation Expenses (including an award to the Lead Plaintiff) should be approved and (v) consider any other matters that may properly be brought before the Court in connection should be approved; and (v) consider any other matters that may properly be brought before the Court in connection If you are a member of the Class, your rights will be affected by the Settlement, and you may be entitled to share

in the Net Settlement Fund. If you have not yet received the full printed Notice of (I) Proposed Settlement and Plan of Allocation; (II) Settlement Hearing; and (III) Motion for Attorneys' Fees and Litigation Expenses (the "Settlement Notice") and the Proof of Claim and Release Form (the "Claim Form"), you may obtain copies of these documents by contacting the Claims Administrator at OvaScience Securities Litigation, c/o Gilardi & Co. LLC, P.O. Box 43312, Providence, RI 02940-3312, 1-866-757-7818, info@OvaScienceSecuritiesLitigation.com. Copies of the Settlement Notice and Claim Form can also be downloaded from the website for the Action, www.OvaScienceSecuritiesLitigation.com.

If you are a Class Member, in order to be eligible to receive a payment under the proposed Settlement, you must submit a Claim Form postmarked (if mailed), or online through the Settlement website, www.OvaScienceSecuritiesLitigation.com, no later than August 22, 2022. If you are a Class Member and do not submit a proper Claim Form, you will not be eligible to share in the distribution of the net proceeds of the Settlement, but you will nevertheless be bound by any judgments or orders entered by the Court in the Action.

If you are a Class Member that did not previously request exclusion from the Class in response to the Notice of Pendency of Class Action, and wish to exclude yourself from the Class, you must submit a written request for exclusion in accordance with the requirements set by the Court and the instructions set forth in the Settlement Notice so that it is postmarked no later than July 5, 2022. If you properly exclude yourself from the Class, you will not be bound by any judgments or orders entered by the Court, whether favorable or unfavorable, and you will not be able to share in the distribution of the Net Settlement Fund.

Any objections to the proposed Settlement, the proposed Plan of Allocation, and/or Lead Counsel's application for attorneys' fees and expenses, must be filed with the Court and delivered to Lead Counsel and counsel for Defendants such that they are received no later than July 5, 2022, in accordance with the instructions set forth in the Settlement

Please do not contact the Court, the Clerk's office, OvaScience, any other Defendants in the Action, or their counsel regarding this notice. All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to the Claims Administrator or Lead Counsel.

Requests for the Settlement Notice and Claim Form should be made to:

OvaScience Securities Litigation c/o Gilardi & Co. LLC P.O. Box 43312 Providence, RI 02940-3312 1-866-757-7818 info@OvaScienceSecuritiesLitigation.com www.OvaScienceSecuritiesLitigation.com

Inquiries, other than requests for the Settlement Notice and Claim Form, may be made to Lead Counsel:

Ellen Gusikoff Stewart, Esq. Robbins Geller Rudman & Dowd LLP 655 West Broadway, Suite 1900 San Diego, CA 92101-8498 1-800-449-4900 elleng@rgrdlaw.com

Dated: April 1, 2022

BY ORDER OF THE COURT United States District Court District of Massachusetts

1 Certain persons and entities are excluded from the Class by definition and others are excluded pursuant to request The full definition of the Class including a complete description of who is excluded from the Class is set forth in the full Settlement Notice referred to above.

BUSINESS OPPORTUNITIES

Well established/branded Seattle software firm est.in 1989 seeking old school or semi-retired ch sales men/women with a book of busines to assist in securing large scale enterprise contracts in the tech, medical, crypto, and or

8% COMMISSION!! 425-256-2815 ask for Phil Anderson SR VP **BUSINESS OPPORTUNITIES**

BUSINESS OPPORTUNITIES

THE WALL STREET JOURNAL.

THEMARKETPLACE

ACCREDITED INVESTORS or BROKER DEALER "DIGITAL COUPON REDEMPTIONS TO SURPASS 90 BILLION IN 2022"

VISIT PILOT PROGRAM - on your cell phone only myqrdiscount.com - division of Savvywellness Call 818-949-1044 to discuss investment

PAWN SHOP FOR SALE TEXAS

steve@stallcupgroup.com

RESIDENTIAL REAL ESTATE



paved-road access, electricity co-op and ground water

Outstanding subdivide development possibility

Located in booming area with high demand Joe Wilson 214 784-3725 jcwilsonranches.com/greenville ADVERTISE TODAY

(800) 366-3975

For more information visit: wsj.com/classifieds



© 2022 Dow Jones & Company, Inc.

DOM JONES

Declaration of Publication

I, Carla Peak, as Vice President, Legal Notification Services at Gilardi & Co. LLC, a KCC Class Action Services Company in San Rafael, California, hereby certify that I caused the attached notice to be printed in said publication on May 6, 2022:

Name of Publication: The Wall Street Journal

Address: 1211 Avenue of the Americas City, State, Zip: New York, NY 10036

Phone #: 1-800-568-7625

State of: New York

I declare under penalty of perjury that the foregoing is true and correct. Executed on this 5th day of May 2022, at Sellersville, Pennsylvania.

Carla Peak

Carla Peak

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the OvaScience, Inc. Securities Settlement

NEWS PROVIDED BY **Robbins Geller Rudman & Dowd LLP →**May 06, 2022, 08:00 ET

SAN DIEGO, May 6, 2022 /PRNewswire/ -- The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the OvaScience, Inc. Securities Settlement:

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

FADI DAHHAN, Individually and on Behalf of All Others Similarly Situated,)	No. 1:17-cv-10511-IT
orran outers offinially officially,)	
Plaintiff,)	<u>CLASS ACTION</u>
vs.)	
)	SUMMARY NOTICE OF (I) PROPOSED
)	SETTLEMENT AND PLAN OF
OVASCIENCE, INC., et al.,)	ALLOCATION; (II) SETTLEMENT
	,	HEARING; AND (III) MOTION FOR
Defendants.)	ATTORNEYS' FEES AND LITIGATION
)	EXPENSES

TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR ACQUIRED OVASCIENCE, INC. ("OVASCIENCE") COMMON STOCK BETWEEN DECEMBER 17, 2014 AND SEPTEMBER 28, 2015, INCLUSIVE (THE "CLASS")¹

PLEASE READ THIS NOTICE CAREFULLY; YOUR RIGHTS WILL BE AFFECTED BY THE SETTLEMENT OF A CLASS ACTION LAWSUIT PENDING IN THIS COURT.

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Massachusetts (the "Court"), that Lead Plaintiff and Class Representative Freedman Family Investments LLC, on behalf of itself and the Court-certified Class in the above-captioned securities class action (the "Action"), has reached a proposed settlement of the Action with defendants OvaScience, Michelle Dipp, Jeffrey E. Young, Longwood Fund, L.P., Longwood Fund, GP, LLC, and Richard Aldrich (collectively, "Defendants") for \$15,000,000 in cash that, if approved, will resolve all claims in the Action.

A hearing will be held on **July 26, 2022, at 2:45 p.m.**, before the Honorable Indira Talwani either in person at the United States District Court for the District of Massachusetts, John Joseph Moakley U.S. Courthouse, I Courthouse Way, Boston, MA 02210, or by telephone or video conference (at the discretion of the Court) to, among other things: (i) determine whether the proposed Settlement on the terms and conditions provided for in the Stipulation and Agreement of Settlement dated March 4, 2022 (the "Stipulation") is fair, reasonable, and adequate to the Class, and should be finally approved by the Court; (ii) determine whether the Action should be dismissed with prejudice against Defendants, and the Releases specified and described in the Stipulation and the Settlement Notice should be granted; (iii) determine whether the proposed Plan of Allocation should be approved as fair and reasonable; (iv) determine whether Lead Counsel's motion for attorneys' fees and Litigation Expenses (including an award to the Lead Plaintiff) should be approved; and (v) consider any other matters that may properly be brought before the Court in connection with the Settlement.

If you are a member of the Class, your rights will be affected by the Settlement, and you may be entitled to share in the Net Settlement Fund. If you have not yet received the full printed Notice of (I) Proposed Settlement and Plan of Allocation; (II) Settlement Hearing; and (III) Motion for Attorneys' Fees and Litigation Expenses (the "Settlement Notice") and the Proof of Claim and Release Form (the "Claim Form"), you may obtain copies of these documents by contacting the Claims Administrator at *OvaScience Securities Litigation*, c/o Gilardi & Co. LLC,

P.O. Box 43312, Providence, RP 02940-3312, 1-866-753-7818, 06/21/22 Page 6 of 16

info@OvaScienceSecuritiesLitigation.com. Copies of the Settlement Notice and Claim Form can also be downloaded from the website for the Action, www.OvaScienceSecuritiesLitigation.com.

If you are a Class Member, in order to be eligible to receive a payment under the proposed Settlement, you must submit a Claim Form postmarked (if mailed), or online through the Settlement website, www.OvaScienceSecuritiesLitigation.com, no later than August 22, 2022. If you are a Class Member and do not submit a proper Claim Form, you will not be eligible to share in the distribution of the net proceeds of the Settlement, but you will nevertheless be bound by any judgments or orders entered by the Court in the Action.

If you are a Class Member that did not previously request exclusion from the Class in response to the Notice of Pendency of Class Action, and wish to exclude yourself from the Class, you must submit a written request for exclusion in accordance with the requirements set by the Court and the instructions set forth in the Settlement Notice so that it is postmarked no later than July 5, 2022. If you properly exclude yourself from the Class, you will not be bound by any judgments or orders entered by the Court, whether favorable or unfavorable, and you will not be able to share in the distribution of the Net Settlement Fund.

Any objections to the proposed Settlement, the proposed Plan of Allocation, and/or Lead Counsel's application for attorneys' fees and expenses, must be filed with the Court and delivered to Lead Counsel and counsel for Defendants such that they are *received* no later than July 5, 2022, in accordance with the instructions set forth in the Settlement Notice.

Please do not contact the Court, the Clerk's office, OvaScience, any other Defendants in the Action, or their counsel regarding this notice. All questions about this notice, the proposed Settlement, or your eligibility to participate in the Settlement should be directed to the Claims Administrator or Lead Counsel.

Requests for the Settlement Notice and Claim Form should be made to:

OvaScience Securities Litigation c/o Gilardi & Co. LLC P.O. Box 43312 Case 1:17-cv-10511-F Document 1873-4-Filed 06/21/22 Page 7 of 16

1-866-757-7818

info@OvaScienceSecuritiesLitigation.com www.OvaScienceSecuritiesLitigation.com

Inquiries, other than requests for the Settlement Notice and Claim Form, may be made to Lead Counsel:

Ellen Gusikoff Stewart, Esq.

Robbins Geller Rudman & Dowd LLP
655 West Broadway, Suite 1900

San Diego, CA 92101-8498

1-800-449-4900

elleng@rgrdlaw.com

DATED: April 1, 2022 BY ORDER OF THE COURT

United States District Court

District of Massachusetts

Media Contact:
Robbins Geller Rudman & Dowd LLP
Shareholder Relations
Rick Nelson
(619) 231-1058

¹ Certain persons and entities are excluded from the Class by definition and others are excluded pursuant to request. The full definition of the Class including a complete description of who is excluded from the Class is set forth in the full Settlement Notice referred to below.

SOURCE Robbins Geller Rudman & Dowd LLP

Declaration of Publication

I, Carla Peak, as Vice President, Legal Notification Services at Gilardi & Co. LLC, a KCC Class Action Services Company in San Rafael, California, hereby certify that I caused the attached notice to be published as a press release by the following wire service:

Name of Publication: PR Newswire

Address: 200 Vesey Street, 19th Floor City, State, Zip: New York, NY 10080

Phone #: 888-776-0942

State of: New York

The press release was distributed on May 6, 2022 to the following media circuits offered by the above-referenced wire service:

1. US1 National Newsline

ala Peak

I declare under penalty of perjury that the foregoing is true and correct. Executed on this 6th day of May 2022, at Sellersville, Pennsylvania.

Carla Peak

Միկիլիուկիովիլիոլիիլիանիրաների արդարանությունների արդանակինիր


L



AGF PORTAL / S

oscince Stanifica It Opilandi I Co. LCC Received MAY 3 11 2022





RECEIVED June 13, 2022 Claims Center

Exclusion Cover Page

Case Name: Ovascience, INC., et al.,

Case Code: OVA

Exclusion Deadline: July 5, 2022 (Postmarked Date)

Name of Person Filing Exclusion: Thomas and Jean Parker Trust
Debra Bachman TTEE
U/A DTD 2/9/2011

June 10, 2022

OvaScience Securities Litigation c/o Gilardi & Co. LLC P.O. 80x 43312 Providence, RI 02940-3312

RE: OvaScience Class Action

Please exclude us from the Class for the settlement. Thomas and Jean Parker deceased in 2018 and 2019. The estate and trust have been settled and are no longer valid.

Thank you,

Debra Bachman TTEE

Thomas and Jean Parker Trust

Ollra Backman TTEE

U/A DTD 02/09/2011

Case 1:17-cv-10511-IT Document 187-3 Filed 06/21/22 Page 12 of 16 Must Be Postmarked (if Mailed) or Received (if Submitted Online) Official No Later Than August 22, 2022 Office UNITED STATES DISTRICT COURT Use **DISTRICT OF MASSACHUSETTS** Only Dahhan v. OvaScience, Inc., et al. Please Type or Print in the Boxes Below No. 1:17-cv-10511-IT Do NOT use Red Ink, Pencil, or Staples PROOF OF CLAIM AND RELEASE PART I. CLAIMANT INFORMATION Please read "General Instructions," above, before completing this "Part I: Claimant Information." The Claims Administrator will use the information provided for all communications regarding this Claim Form. If this information changes, you MUST notify the Claims Administrator in writing at the address above. Complete names of all persons and entities must be provided. Last Name (vin in the last Name) M.I. First Name Last Name (Co-Beneficial Owner) M.L First Name (Co-Beneficial Owner) ● IRA : • Joint Tenancy :: • ☐ Employee :: :::: O Individual (III) O Other Company Name (Beneficial Owner alf Claimant is not an Individual) or Custodian Name if an IRA (specify) Trustee/Asset Manager/Nominee/Record Owner's Name (If Different from Beneficial Owner Listed Above) Account#/Fund# (Not Necessary for Individual Filers) Last Four Digits of Social Security Number Taxpayer Identification Number Telephone Number.(Primary Daytime) Telephone Number (Alternate) Email Address MAILING INFORMATION Address City has the course of the cou State ZIP Code Foreign Country Name/Abbreviation Foreign Postal Code BB DR S PL



FOR CLAIMS PROCESSING

O RE

FOR CLAIMS PROCESSING ONLY

Case 1:17-cv-10511-IT Document 187-3 Filed 06/21/22 Page 13 of 16

PART II. SCHEDULE OF TRANSACTIONS IN OVASCIENCE COMMON STOCK

(NASDAQ TICKER: OVAS; CUSIP 69014Q)Use this section to provide information on your holdings and trading of OvaScience common stock (NASDAQ Ticker Symbol: OVAS) ("OvaScience common stock") during the requested time periods. Please include proper documentation with your Claim Form as described in detail in the General Instructions, Paragraph 8 above.

A Number of shares of OvaScience common at the close of trading on December 18, 20	stock held		Proof Enclosed?
B. Purchases and acquisitions (including free recommendation) PURCHASES	receipts) of OvaScience common stock	(December 17, 2014 – September 28	, 2015, inclusive):
Trade Date(s) of Shares (List Chronologically)	Number of Shares Purchased or Acquired	Total Purchase or Acquisition Price (Excluding Commissions, Taxes and Fees). Please round off to the nearest whole dollar	Proof of Purchase Enclosed?
].00 82
		\$	
6. // //			
 Number of shares of OvaScience common (including free receipts) from September, 29. 	stock purchased of acquired (4) 2015 through December 28, 2015:1		Proof Enclosed?
(IMPORTANT: (i) If any purchase listed covered (ii) If you received shares through an acquisition (iii) If you	or merger, please identify the date it	Company:	ired in the control of the control o
Trade Date(s) of Shares (List Chronologically)	Number of Shares Sold	Total Sales Price (Excluding Commissions, Taxes and Fees). Please round off to the nearest whole dollar	Proof of Sales Enclosed?
		Š].[00].[8 _N
2/// 3///		\$	
4.		\$	PORTUGINATION AND A SECOND
	· · · · · · · · · · · · · · · · · · ·	\$].[00] 8x

If you require additional space, attach extra schedules in the same format as above. Sign and print your name on each additional page.

YOU MUST READ AND SIGN THE RELEASE ON PAGE 6. FAILURE TO SIGN THE RELEASE MAY RESULT IN A DELAY IN PROCESSING OR THE REJECTION OF YOUR CLAIM.



PART III. RELEASE OF CLAIMS AND SIGNATURE

YOU MUST ALSO READ THE RELEASE AND CERTIFICATION BELOW AND SIGN ON PAGE 6 OF THIS CLAIM FORM.

I (We) hereby acknowledge that, pursuant to the terms set forth in the Stipulation, without further action by anyone, upon the Effective Date of the Settlement, I (we), on behalf of myself (ourselves) and my (our) (the Claimant(s)') heirs, executors, administrators, predecessors, successors, and assigns in their capacities as such, shall be deemed to have, and by operation of law and of the judgment shall have, fully, finally, and forever compromised, settled, released, resolved, relinquished, waived, and discharged any and all Released Plaintiff's Claims against Defendants and the other Defendants' Releasees, and shall forever be barred and enjoined from prosecuting any and all Released Plaintiff's Claims against any of the Defendants' Releasees, whether or not such Class Member executes and delivers the Claim Form or shares in the Net Settlement Fund.

PART IV. CERTIFICATION

By signing and submitting this Claim Form, the Claimant(s) or the person(s) who represent(s) the Claimant(s) agree(s) to the release above and certifies (certify) as follows:

- (a) that I (we) have read and understand the contents of the Notice and this Claim Form, including the releases provided for in the Settlement and the terms of the Plan of Allocation;
- (b) that the Claimant(s) is a (are) Class Member(s), as defined in the Notice, and is (are) not excluded by definition from the Class as set forth in the Notice;
- (c) that I (we) own(ed) the OvaScience common stock identified in the Claim Form and have not assigned the Claim against any of the Defendants or any of the other Defendants' Releasees to another, or that, in signing and submitting this Claim Form, I (we) have the authority to act on behalf of the owner(s) thereof;
- (d) that the Claimant(s) has (have) not submitted any other Claim covering the same purchases or acquisitions of OvaScience common stock and knows (know) of no other person having done so on the Claimant's (Claimants') behalf;
- (e) that the Claimant(s) submit(s) to the jurisdiction of the Court with respect to Claimant's (Claimants') Claim and for purposes of enforcing the releases set forth herein;
- (f) that I (we) agree to furnish such additional information with respect to this Claim Form as Lead Counsel, the Claims Administrator, or the Court may require;
- (g) that the Claimant(s) waive(s) the right to trial by jury, to the extent it exists, and agree(s) to the determination by the Court of the validity or amount of this Claim, and waives any right of appeal or review with respect to such determination;
- (h) that I (we) acknowledge that the Claimant(s) will be bound by and subject to the terms of any judgment(s) that may be entered in the Action; and
- (i) that the Claimant(s) is (are) NOT subject to backup withholding under the provisions of Section 3406(a)(1) (C) of the Internal Revenue Code because (i) the Claimant(s) is (are) exempt from backup withholding or (ii) the Claimant(s) has (have) not been notified by the IRS that he, she, or it is subject to backup withholding as a result of a failure to report all interest or dividends or (iii) the IRS has notified the Claimant(s) that he, she, or it is no longer subject to backup withholding. If the IRS has notified the Claimant(s) that he, she, it, or they is (are) subject to backup withholding, please strike out the language in the preceding sentence indicating that the Claim is not subject to backup withholding in the certification above.

Information requested with respect to your purchases and acquisitions of OvaScience common stock from September 29, 2015 through and including December 28, 2015, is needed in order to balance your claim; purchases during this period, however, are not eligible under the Settlement and will not be used for purposes of calculating your Recognized Claim under the Plan of Allocation.



UNDER THE PENALTIES OF PERJURY, I (WE) CERTIFY THAT ALL OF THE INFORMATION PROVIDED BY ME (US) ON THIS CLAIM FORM IS TRUE, CORRECT, AND COMPLETE, AND THAT THE DOCUMENTS SUBMITTED HEREWITH ARE TRUE AND CORRECT COPIES OF WHAT THEY PURPORT TO BE.

Executed this	day of	in
	(Month	Year) (City/State/Country)
(Sign your name here)		(Sign your name here)
(Type or print your name here)		(Type or print your name here)
(Capacity of person(s) signing, Beneficial Purchaser or Acquir	-	(Capacity of person(s) signing, e.g., Beneficial Purchaser or Acquirer, Executor or Administrator)

ACCURATE CLAIMS PROCESSING TAKES A SIGNIFICANT AMOUNT OF TIME. THANK YOU FOR YOUR PATIENCE.

Reminder Checklist:

- 1. Please sign the above release and certification.
- 2. If this Claim Form is being made on behalf of Joint Claimants, then both must sign.
- 3. Remember to attach copies of supporting documentation, if available.
- Attach only copies of acceptable supporting documentation as these documents will not be returned to you.
- Keep a copy of your Claim Form and all supporting documentation for your records.
- If you desire an acknowledgment of receipt of your Claim Form, please send it Certified Mail, Return Receipt Requested.

- 7. Do not use red pen or highlighter on the Claim Form or supporting documentation.
- 8. If your address changes in the future, or if this Claim Form was sent to an old or incorrect address, you must send the Claims Administrator written notification of your new address. If you change your name, inform the Claims Administrator.
- If you have any questions or concerns regarding your Claim, please contact the Claims Administrator at the address below, by email at info@OvaScienceSecuritiesLitigation.com, or by toll-free phone at 1 (866) 757-7818, or you may visit www.OvaScienceSecuritiesLitigation.com. DO NOT call OvaScience or its counsel with questions regarding your Claim.

THIS CLAIM FORM MUST BE SUBMITTED ONLINE USING THE SETTLEMENT WEBSITE, WWW.OVASCIENCESECURITIESLITIGATION.COM, NO LATER THAN AUGUST 22, 2022, OR MAILED TO THE CLAIMS ADMINISTRATOR BY FIRST-CLASS MAIL, POSTMARKED NO LATER THAN AUGUST 22, 2022, ADDRESSED AS FOLLOWS:

OvaScience Securities Litigation c/o Gilardi & Co. LLC P.O. Box 43312 Providence, RI 02940-3312

A Claim Form received by the Claims Administrator via mail shall be deemed to have been submitted when posted, if a postmark date on or before August 22, 2022 is indicated on the envelope and it is mailed First Class, and addressed in accordance with the above instructions. In all other cases, a Claim Form shall be deemed to have been submitted when actually received by the Claims Administrator.

You should be aware that it will take a significant amount of time to fully process all of the Claim Forms. Please be patient and notify the Claims Administrator of any change of address.





10 JUN 2022 PM 6 L


RECEIVED JUN 1 3 2022

OvaScience Securities Litigation c/o Gilardi & Co. LLC P.O. Box 43312 Providence, RI 02940-3312

OVA

<u>Իրհիկիստիկումիրիկիկիկինումիկունումիկինի</u>

EXHIBIT D



RECEIVED May 31, 2022 Claims Center

Exclusion Cover Page

Case Name: Ovascience, INC., et al.,

Case Code: OVA

Exclusion Deadline: July 5, 2022 (Postmarked Date)

Name of Person Filing Exclusion: Carlos Alberto Rodrigues Alves Sylvia de Lourdes Rodriguez Alves

São Paulo, 12thMay, 2022

OvaScience Securities Litigation

C/o Gilardi & Co LLC

PO Box 43312

Providence, RI 02940-3312

Ref Fadi Dahhan – no, 1:17 – cv 10511 – IT

According to what we have already stated in our letter of 25th August 2020, we, Carlos Alberto Rodrigues Alves and Sylvia de Lourdes Rodrigues Alves, resident at respectfully request the exclusion os our names as members of the Class, regarding the class action mentioned.

arlos Alberto Rodrigues Alves

Sylvia de Lyurdes Rodrigues Alves


L



AGF PORTAL / S

oscince Stanifica It Opilandi I Co. LCC Received MAY 3 11 2022





RECEIVED June 13, 2022 Claims Center

Exclusion Cover Page

Case Name: Ovascience, INC., et al.,

Case Code: OVA

Exclusion Deadline: July 5, 2022 (Postmarked Date)

Name of Person Filing Exclusion: Thomas and Jean Parker Trust
Debra Bachman TTEE
U/A DTD 2/9/2011

June 10, 2022

OvaScience Securities Litigation c/o Gilardi & Co. LLC P.O. 8ox 43312 Providence, RI 02940-3312

RE: OvaScience Class Action

Please exclude us from the Class for the settlement. Thomas and Jean Parker deceased in 2018 and 2019. The estate and trust have been settled and are no longer valid.

Thank you,

Debra Bachman TTEE

Thomas and Jean Parker Trust

Ollra Backman TTEE

U/A DTD 02/09/2011

Case 1:17-cv-10511-IT Document 187-4 Filed 06/21/22 Page 7 of 11 Must Be Postmarked (if Mailed) or Received (if Submitted Online) Official No Later Than August 22, 2022 Office UNITED STATES DISTRICT COURT Use **DISTRICT OF MASSACHUSETTS** Only Dahhan v. OvaScience, Inc., et al. Please Type or Print in the Boxes Below No. 1:17-cv-10511-IT Do NOT use Red Ink, Pencil, or Staples PROOF OF CLAIM AND RELEASE PART I. CLAIMANT INFORMATION Please read "General Instructions," above, before completing this "Part I: Claimant Information." The Claims Administrator will use the information provided for all communications regarding this Claim Form. If this information changes, you MUST notify the Claims Administrator in writing at the address above. Complete names of all persons and entities must be provided. Last Name (vin in the last Name) M.I. First Name Last Name (Co-Beneficial Owner) M.L First Name (Co-Beneficial Owner) ● IRA : • Joint Tenancy :: • ☐ Employee :: :::: O Individual (III) O Other Company, Name (Beneficial Owner - if Claimant is not an Individual) or Custodian Name if an IRA (specify) Trustee/Asset Manager/Nominee/Record Owner's Name (If Different from Beneficial Owner Listed Above) Account#/Fund# (Not Necessary for Individual Filers) Last Four Digits of Social Security Number Taxpayer Identification Number Telephone Number.(Primary Daytime) Telephone Number (Alternate) Email Address MAILING INFORMATION Address City has the course of the cou State ZIP Code Foreign Country Name/Abbreviation Foreign Postal Code



FOR CLAIMS PROCESSING S PL

O RE

FOR CLAIMS PROCESSING ONLY

BB DR

Case 1:17-cv-10511-IT Document 187-4 Filed 06/21/22 Page 8 of 11

PART II. SCHEDULE OF TRANSACTIONS IN OVASCIENCE COMMON STOCK

(NASDAQ TICKER: OVAS; CUSIP 69014Q)Use this section to provide information on your holdings and trading of OvaScience common stock (NASDAQ Ticker Symbol: OVAS) ("OvaScience common stock") during the requested time periods. Please include proper documentation with your Claim Form as described in detail in the General Instructions, Paragraph 8 above.

A SECURITY OF THE PROPERTY OF

at the	close of trading on December 18, 20	stock held		Proof Enclosed?
B. Purch	ases and acquisitions (including free PURCHASES	receipts) of OvaScience common stock (E	December 17, 2014 – September 28,	2015, inclusive):
	Trade Date(s) of Shares (List Chronologically)	Number of Shares Purchased or Acquired	Total Purchase or Acquisition Price (Excluding Commissions, Taxes and Fees). Please round off to the nearest whole dollar	Proof of Purchase Enclosed?
M	M DD: YYY		क्षेत्र के के कार्य कर्ता कार्य कर्ता कर्ता कर्ता कर्ता कर	· 通り車を乗る () 通行 () ・
1		S		
2		S	A STATE OF THE STA	J.@.8 _N
3.				
4		43		$\bigcap_{i} \bigotimes_{N}^{Y_{i}}$
6.		is s].[00] 8 _N .
© (Numit	per of shares of OvaScience common ding free receipts) from September 29	stock purchased of acquired 444444444444444444444444444444444444		roof Enclosed?
IMPORTA	ALT THE STATE OF T	a "short sale," please mark Yes: OYes	· 曹子 不舍 对为 哪个 衛子 斯尔特 化氯化 原料 新知 新 写 高 是 () (· · · · · · · · · · · · · · · · ·	Padaga aliphiada ka 1
(II) (N (X)	eceived chare: (incugin an acquisitio	n or merger, please identify the date, the	share amount and the company acquired Company:	lired in
(II) Inyour (M) (M) D. Sales	D D V V V V (including free deliveries) of OvaScience	n or merger, please identify the date, the Merger Shares:		Jired Market Control of the Control
(ii) (ivyou M) (M) D. Sales	D D V V V V Including free deliveries) of OvaScie SALES Trade Date(s) of Shares (List Chronologically)	Merger Shares: Merger Shares: Number of Shares Sold	- December 28, 2015, inclusive): Total Sales Price (Excluding Commissions, Taxes and Fees). Please round off to the nearest whole dollar	Proof of Sales Enclosed?
(ii) (i you M M D. Sales	D D V V V V (including free deliveries) of OvaScie SALES Trade Date(s) of Shares	n or merger, please identify the date) the Merger Shares: Merger Shares: Number of Shares Sold	- December 28, 2015, inclusive): Total Sales Price (Excluding Commissions, Taxes and Fees). Please round off to the nearest whole dollar	Proof of Sales Enclosed?
(ii) (iyou M M D. Sales	D D V V V V (including free deliveries) of OvaScle SALES Trade Date(s) of Shares (List Chronologically)	n or merger, please identify the date) the Merger Shares: Pence common stock (December 17, 2014 Number of Shares Sold	- December 28, 2015, inclusive): Total Sales Price (Excluding Commissions, Taxes and Fees). Please round off to the nearest whole dollar	Proof of Sales Enclosed?
(ii) (i you M M D. Sales	D D V V V V (including free deliveries) of OvaScle SALES Trade Date(s) of Shares (List Chronologically)	n or merger, please identify the date) the Merger Shares: ence common stock (December 17, 2014 Number of Shares Sold	- December 28, 2015, inclusive): Total Sales Price (Excluding Commissions, Taxes and Fees). Please round off to the nearest whole dollar	Proof of Sales Enclosed?
(II) (IA) YOU ON MARKET	eceived shares through an acquisition D D V V V V (including free deliveries) of OvaScie SALES Trade Date(s) of Shares (List Chronologically) M D D V V V V	n or merger, please identify the date, the Merger Shares: Merger Shares: Number of Shares Sold	- December 28, 2015, inclusive): Total Sales Price (Excluding Commissions, Taxes and Fees). Please round off to the nearest whole dollar	Proof of Sales Enclosed?
(II) (IA) YOU ON MARKET	eceived shares through an acquisition D D Y Y Y Y (including free deliveries) of OvaScie SALES Trade Date(s) of Shares (List Chronologically) M D D Y Y Y (including free deliveries) of OvaScie SALES	Number of Shares Sold	- December 28, 2015, inclusive): Total Sales Price (Excluding Commissions, Taxes and Fees). Please round off to the nearest whole dollar	Proof of Sales Enclosed?
(II) (IA) YOU ON MARKET	eceived shares through an acquisition D D Y Y Y Y (including free deliveries) of OvaScie SALES Trade Date(s) of Shares (List Chronologically) M D D Y Y Y (including free deliveries) of OvaScie SALES	n or merger, please identify the date) the Merger Shares: ence common stock (December 17, 2014 Number of Shares Sold	- December 28, 2015, inclusive): Total Sales Price (Excluding Commissions, Taxes and Fees). Please round off to the nearest whole dollar	Proof of Sales Enclosed?

If you require additional space, attach extra schedules in the same format as above. Sign and print your name on each additional page.

YOU MUST READ AND SIGN THE RELEASE ON PAGE 6. FAILURE TO SIGN THE RELEASE MAY RESULT IN A DELAY IN PROCESSING OR THE REJECTION OF YOUR CLAIM.



PART III. RELEASE OF CLAIMS AND SIGNATURE

YOU MUST ALSO READ THE RELEASE AND CERTIFICATION BELOW AND SIGN ON PAGE 6 OF THIS CLAIM FORM.

I (We) hereby acknowledge that, pursuant to the terms set forth in the Stipulation, without further action by anyone, upon the Effective Date of the Settlement, I (we), on behalf of myself (ourselves) and my (our) (the Claimant(s)') heirs, executors, administrators, predecessors, successors, and assigns in their capacities as such, shall be deemed to have, and by operation of law and of the judgment shall have, fully, finally, and forever compromised, settled, released, resolved, relinquished, waived, and discharged any and all Released Plaintiff's Claims against Defendants and the other Defendants' Releasees, and shall forever be barred and enjoined from prosecuting any and all Released Plaintiff's Claims against any of the Defendants' Releasees, whether or not such Class Member executes and delivers the Claim Form or shares in the Net Settlement Fund.

PART IV. CERTIFICATION

By signing and submitting this Claim Form, the Claimant(s) or the person(s) who represent(s) the Claimant(s) agree(s) to the release above and certifies (certify) as follows:

- (a) that I (we) have read and understand the contents of the Notice and this Claim Form, including the releases provided for in the Settlement and the terms of the Plan of Allocation;
- (b) that the Claimant(s) is a (are) Class Member(s), as defined in the Notice, and is (are) not excluded by definition from the Class as set forth in the Notice;
- (c) that I (we) own(ed) the OvaScience common stock identified in the Claim Form and have not assigned the Claim against any of the Defendants or any of the other Defendants' Releasees to another, or that, in signing and submitting this Claim Form, I (we) have the authority to act on behalf of the owner(s) thereof;
- (d) that the Claimant(s) has (have) not submitted any other Claim covering the same purchases or acquisitions of OvaScience common stock and knows (know) of no other person having done so on the Claimant's (Claimants') behalf;
- (e) that the Claimant(s) submit(s) to the jurisdiction of the Court with respect to Claimant's (Claimants') Claim and for purposes of enforcing the releases set forth herein;
- (f) that I (we) agree to furnish such additional information with respect to this Claim Form as Lead Counsel, the Claims Administrator, or the Court may require;
- (g) that the Claimant(s) waive(s) the right to trial by jury, to the extent it exists, and agree(s) to the determination by the Court of the validity or amount of this Claim, and waives any right of appeal or review with respect to such determination;
- (h) that I (we) acknowledge that the Claimant(s) will be bound by and subject to the terms of any judgment(s) that may be entered in the Action; and
- (i) that the Claimant(s) is (are) NOT subject to backup withholding under the provisions of Section 3406(a)(1) (C) of the Internal Revenue Code because (i) the Claimant(s) is (are) exempt from backup withholding or (ii) the Claimant(s) has (have) not been notified by the IRS that he, she, or it is subject to backup withholding as a result of a failure to report all interest or dividends or (iii) the IRS has notified the Claimant(s) that he, she, or it is no longer subject to backup withholding. If the IRS has notified the Claimant(s) that he, she, it, or they is (are) subject to backup withholding, please strike out the language in the preceding sentence indicating that the Claim is not subject to backup withholding in the certification above.

5



Information requested with respect to your purchases and acquisitions of OvaScience common stock from September 29, 2015 through and including December 28, 2015, is needed in order to balance your claim; purchases during this period, however, are not eligible under the Settlement and will not be used for purposes of calculating your Recognized Claim under the Plan of Allocation.

UNDER THE PENALTIES OF PERJURY, I (WE) CERTIFY THAT ALL OF THE INFORMATION PROVIDED BY ME (US) ON THIS CLAIM FORM IS TRUE, CORRECT, AND COMPLETE, AND THAT THE DOCUMENTS SUBMITTED HEREWITH ARE TRUE AND CORRECT COPIES OF WHAT THEY PURPORT TO BE.

Executed this	day of	in
	(Month	Year) (City/State/Country)
(Sign your name here)		(Sign your name here)
(Type or print your name here)		(Type or print your name here)
(Capacity of person(s) signing, Beneficial Purchaser or Acquir	-	(Capacity of person(s) signing, e.g., Beneficial Purchaser or Acquirer, Executor or Administrator)

ACCURATE CLAIMS PROCESSING TAKES A SIGNIFICANT AMOUNT OF TIME. THANK YOU FOR YOUR PATIENCE.

Reminder Checklist:

- 1. Please sign the above release and certification.
- 2. If this Claim Form is being made on behalf of Joint Claimants, then both must sign.
- 3. Remember to attach copies of supporting documentation, if available.
- Attach only copies of acceptable supporting documentation as these documents will not be returned to you.
- 5. Keep a copy of your Claim Form and all supporting documentation for your records.
- If you desire an acknowledgment of receipt of your Claim Form, please send it Certified Mail, Return Receipt Requested.

- 7. Do not use red pen or highlighter on the Claim Form or supporting documentation.
- 8. If your address changes in the future, or if this Claim Form was sent to an old or incorrect address, you must send the Claims Administrator written notification of your new address. If you change your name, inform the Claims Administrator.
- If you have any questions or concerns regarding your Claim, please contact the Claims Administrator at the address below, by email at info@OvaScienceSecuritiesLitigation.com, or by toll-free phone at 1 (866) 757-7818, or you may visit www.OvaScienceSecuritiesLitigation.com. DO NOT call OvaScience or its counsel with questions regarding your Claim.

THIS CLAIM FORM MUST BE SUBMITTED ONLINE USING THE SETTLEMENT WEBSITE, WWW.OVASCIENCESECURITIESLITIGATION.COM, NO LATER THAN AUGUST 22, 2022, OR MAILED TO THE CLAIMS ADMINISTRATOR BY FIRST-CLASS MAIL, POSTMARKED NO LATER THAN AUGUST 22, 2022, ADDRESSED AS FOLLOWS:

OvaScience Securities Litigation c/o Gilardi & Co. LLC P.O. Box 43312 Providence, RI 02940-3312

A Claim Form received by the Claims Administrator via mail shall be deemed to have been submitted when posted, if a postmark date on or before August 22, 2022 is indicated on the envelope and it is mailed First Class, and addressed in accordance with the above instructions. In all other cases, a Claim Form shall be deemed to have been submitted when actually received by the Claims Administrator.

You should be aware that it will take a significant amount of time to fully process all of the Claim Forms. Please be patient and notify the Claims Administrator of any change of address.





10 JUN 2022 PM 6 1

RECEIVED JUN 1 3 2022

OvaScience Securities Litigation c/o Gilardi & Co. LLC P.O. Box 43312 Providence, RI 02940-3312

OVA

<u>Իրհիկիստիկումիրիկիկիկինումիկունումիկինի</u>